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PUBLICATIONS AND PRESENTATIONS 
The National Health and Medical Research Council Clinical 
Trials Centre has the purpose of improving outcomes in 
health through clinical trials research. It was established by the 
National Health and Medical Research Council in 1988 as a 
research centre at the University of Sydney.
The CTC provides the knowledge and infrastructure to ensure 
the quality, timely completion and reporting of clinical trials. 
It has vast expertise in the design, conduct and analysis 
of randomised controlled trials, particularly in cancer and 
cardiovascular disease. Over 100 staﬀ  have specialised skills, 
taking in clinical trials design, biostatistics, database design, 
randomisation and drug distribution, outcome assessment, 
quality assurance, and regulatory and ethical issues. In the past 
16 years, the CTC has participated in more than 50 investigator-
initiated, collaborative-group clinical trials and coordinated 
some of the largest randomised trials initiated by Australian 
investigators (LIPID and FIELD studies, each with over 9000 
patients). Over 40 000 patients have been randomised to 
these trials. All clinical trials undertaken through the CTC are 
conducted strictly according to guidelines for clinical trials 
research and conduct, and are audited by sponsors, the CTC 
itself and regulatory authorities.
The CTC has a history of working collaboratively with 
cooperative groups, clinical trial networks and other 
organisations, and has played a central role in establishing 
some of these groups. These activities have been recognised in 
increased grant funding to enable further collaboration and to 
increase the number of investigator-initiated trials in Australia. 
In its research, the CTC has prospered: it has developed 
strategies for patient recruitment, trial and data management, 
study coordination, information systems and randomisation 
in an environment of academic excellence. In addition to trials 
management, the CTC is a leader in biostatistical methodology 
and analysis and in systematic review of health evidence. The 
integrated expertise of the CTC staﬀ  is turned to good use in 
frequent educational activities in Australia and elsewhere.
This report covers the CTC’s achievements for the biennium, 
2004–2005.
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BRINGING AN EVIDENCE BASE TO DECISION MAKING AND POLICY: ACTR
The past two years has seen the CTC follow a research direction 
which has three major strands: 
• initiating major clinical trials in high-priority disease areas 
commonly aﬀ ecting the Australian population 
• advances in methods for understanding clinical trials and for 
using evidence from trials
• combining results from trials to improve the quality of the 
evidence and integrating that evidence with information 
about risks and preferences of individual patients. 
Ultimately, we aim to generate better research evidence and 
narrow the gap between research evidence and practice.  
Focusing on high-priority questions and trials that beneﬁ t most 
from the CTC’s strengths is a major research theme. New trials 
have a long gestation; we review existing evidence, acquire 
funding, build collaborations, achieve agreement among the 
collaborators about the research question, and conduct pilot 
studies, all before a major trial is launched.
The CTC has a policy of conducting trials of most value to the 
health of the Australian population. Thromboses, or blood 
clots, sometimes occur after major surgery or during pregnancy, 
but sometimes they occur for no apparent reason. The ASPIRE 
trial, which is using aspirin treatment to prevent unprovoked 
recurrence of deep-vein thrombosis or pulmonary embolism, 
was set up in 2003 and is now in recruitment. If eﬀ ective, this 
simple and inexpensive treatment could prevent recurrent 
thrombosis in thousands of patients each year, potentially 
leading to substantial healthcare savings. It is also part of an 
international prospective meta-analysis, which will challenge 
and strengthen its ﬁ ndings. We have started new trials to 
improve the health of newborn babies: ﬁ rst INIS, a trial of 
preventing the serious long-term eﬀ ects of infection, and now 
BOOST II, which is attempting to ﬁ nd the optimum level of 
oxygen treatment for premature babies.
One of the CTC’s recent successes has been the SNAC trial, 
which arose initially from the concerns of women with breast 
cancer about the complications of breast surgery. That the 
research question was relevant to patients was conﬁ rmed by 
SNAC’s rapid recruitment of over 1000 women. We are now 
establishing SNAC 2, which will recruit more women and 
extend the amount and type of information we will acquire 
from the trial. Like the ﬁ rst trial, this is a collaboration with the 
Royal Australasian College of Surgeons.
The CTC has recently received funding for major enabling 
activities. Recent grants to the CTC and its collaborative groups 
in cancer is enabling the CTC to move ahead with applying 
its generic systems and expertise to many diﬀ erent trials, our 
own and others’. Cancer trial initiatives in association with 
the Australasian Gastro-Intestinal Trials Group and the new 
Australia New Zealand Gynaecological Oncology Group are 
under way.
Late in 2005 the main results of the FIELD study were presented 
and simultaneously published in The Lancet. FIELD, the largest 
completed trial worldwide in diabetes, with almost 10,000 
patients, was designed to test whether fenoﬁ brate can prevent 
heart attack, death from coronary heart disease and other major 
vascular events. The results of FIELD were mixed; fenoﬁ brate did 
not signiﬁ cantly reduce the risk of a major coronary event (the 
primary trial outcome measured), but the trial result showed 
that fenoﬁ brate reduced the number of cardiovascular events 
overall, including nonfatal heart attack and hospitalisation 
for angina. The drug also beneﬁ ted patients in reducing the 
need for procedures such as coronary artery bypass grafting, 
amputations and laser treatments for eyes. FIELD was a major 
undertaking of the CTC. Initial discussions about the feasibility 
of such a trial began over 10 years ago, when it was known 
that fenoﬁ brate and similar drugs were particularly suited to 
improving the blood lipids of people with diabetes and that 
fenoﬁ brate reduced plaque in arteries. This large trial resolved 
much of the uncertainty about its clinical eﬀ ects. The trial results 
are also guiding clinicians on the use of fenoﬁ brate for patients 
with type 2 diabetes and reassuring them as to its overall safety, 
alone and in combination with other drugs. 
The power of  studying a large number of patients was 
shown by the results of the Cholesterol Treatment Trialists’ 
Collaboration, also published late in 2005. The collaboration 
ﬁ rst designed this prospective meta-analysis in 1994. The 
ﬁ rst cycle of the study was an analysis of data from 14 trials, 
comprising 90 056 patients, of statin drugs to lower cholesterol 
and reduce the risk of cardiovascular disease. The results 
provided deﬁ nitive evidence that substantial reductions in LDL 
cholesterol with statin treatment beneﬁ t patients with a high 
risk of any type of occlusive vascular event. Most trials are tied to 
studying a single main outcome (a speciﬁ c kind of event, such 
as death or stroke) because cost limits the sample size. Meta-
analysis combines data from multiple trials and patients, but the 
analysis may lead to conﬂ icting conclusions.The results of the 
CTTC prospective meta-analysis therefore represent an advance 
in knowledge brought about by an advance in methods. The 
CTC is co-coordinator of the collaboration (with the Clinical Trial 
Service Unit and Epidemiological Studies Unit in the UK).
In 2005 the Australian Clinical Trials Registry was established 
at the CTC with funding from the National Health and Medical 
Research Council. We have been aware for many years of the 
advantages of public registration of trials in progress. The 
registry is the realisation of an ideal that has been 20 years in 
F R O M  T H E  D I R EC T O R S
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John Simes
Director
John Simes is the 
foundation director of 
the CTC and continues 
to direct all the CTC’s 
activities. He is recognised 
internationally for 
his expertise in the 
ﬁ elds of clinical trials 
and biostatistics and 
represents the CTC on 
many national and 
international committees. 
He has fostered clinical trials and clinical trial networks in 
cancer, cardiovascular medicine, thrombosis, neonatal medicine 
and surgery. He has played a leading role in many international 
trials that have led to major advances in health care and has for 
many years championed the need for evidence-based clinical 
research. 
Professor Simes is also professor in the departments of 
Medicine and Public Health and Community Medicine at the 
University of Sydney, and is a specialist medical oncologist at 
Royal Prince Alfred Hospital. 
Anthony Keech
Deputy director
Anthony Keech, 
cardiologist and 
epidemiologist, co-directs 
the CTC research program. 
He is professor in the 
Department of Medicine 
at the University of 
Sydney and a leading 
international ﬁ gure in lipid 
and cardiovascular clinical 
trials. Professor Keech is 
chairman of the FIELD 
study on heart disease and diabetes, the largest trial of patients 
with diabetes and the largest trial ever conducted in Australia, 
which was completed in 2005. He is also a practising consultant 
cardiologist at Royal Prince Alfred Hospital.
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the making, after it was shown in the 1980s that published 
research may present a biased picture. A signiﬁ cant proportion 
of trials research is never published, leading to wasted eﬀ ort by 
researchers and patients and bias in the published evidence. 
As well, knowledge of ongoing trials prevents unnecessary 
duplication of research. The new register has a complete and 
comprehensive catalogue of all clinical trials in Australia. 
It will lead to the conduct of more relevant and timely and 
hence more ethical clinical research and aims to oﬀ er a reliable 
and unbiased source of information for systematic reviews, 
prospective meta-analyses and evidence-based guidelines. The 
register is an essential part of our strategy for improving health 
outcomes through better use of clinical trials research. 
Achievements in statistics have included methods for selecting 
sample sizes in designs when the eﬀ ects of two diﬀ erent 
treatments inﬂ uence each other, new ways with dynamic 
randomisation methodology, and how to assess surrogate 
outcomes when some data are unavailable.
Integrating trial evidence with other information about patients 
can improve clinical decision making. Researchers at the CTC 
have been focusing on studies of patients’ preferences about 
cancer treatment. We have used established results of trials 
of various treatments for breast cancer to look in the other 
direction and ask women themselves to what degree the 
treatments were worthwhile. These studies have suggested 
that surprisingly small beneﬁ ts may be suﬃ  cient to justify 
treatments.
Another approach to applying trial evidence to real patients has 
been work on prognostic models. Risk-factor models are being 
constructed as decision aids for identifying patients at high risk; 
in those who are at high risk, the absolute beneﬁ t of treatment 
is often greater. Development of risk models and other clinical 
and methodological advances are possible because of the 
accumulated data sets and long-standing research expertise of 
the CTC and its collaborators.
One of the CTC’s objectives is to pass on the expertise gained 
through our experience in collaborative trials research. 
Academic staﬀ  members of the CTC teach and administer 
graduate training courses at the University of Sydney and other 
universities. Senior staﬀ  supervise higher degree students 
working on projects that are crucial to the CTC’s research 
aspirations. In addition, several CTC research staﬀ  have been 
recently awarded doctoral degrees. Their projects are an integral 
part of the CTC’s research program. 
The considerable achievements of the CTC in the past two years 
have been a result of dedicated cooperative eﬀ ort from staﬀ  
members of the CTC and their research colleagues. The research 
program owes its strength to the support of government and 
industry funding bodies, national and international clinical 
investigator groups and other sponsors.
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ORGANISATION AND EXECUTIVE
CTC EXECUTIVE
At right (left to right): 
Wendy Hague, director of 
the clinical trials program, 
John Simes, director, and 
Anthony Keech, deputy 
director.
At left: Dorothea Sophia, who retired in 
2005, was business manager of the CTC with 
responsibility for the CTC’s business services.
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Granting body Project 2004 2005
National Health and Medical Research Council Program grant 1 315 000 1 353 799
National Health and Medical Research Council Research fellowships 291 000 317 641
National Health and Medical Research Council Clinical trials 894 575 1 360 979
National Health and Medical Research Council Australian Clinical Trials Registry — 120 000
University of Sydney Infrastructure and institute grants 804 235 805 586
University of Sydney Cancer Research Fund Patients’ preferences study 47 500 —
Department of Health and Ageing Reviews of medical technologies and procedures 406 204 712 862
Department of Health and Ageing Biostatistics Collaboration of Australia 146 095 69 020
Department of Health and Ageing Cochrane reviews 60 000 55 000
Department of Education, Science and Training Clinical Trials and Data Information Network 470 000 —
NSW Department of Health ASPIRE study 50 000 62 500
NSW Cancer Council Cancer trials 65 425 137 132
NSW Cancer Council Cochrane systematic reviews — 6 053
NSW Cancer Institute Infrastructure support for 
cancer trials (partnership grant)
— 641 694
National Breast Cancer Council Cochrane systematic reviews — 5 404
National Breast Cancer Foundation SNAC study 49 727 141 600
Cure Cancer Australia Breast cancer systematic review — 34 622
Cancer Council Australia SCOTROC study — 30 000
SA Cancer Council ZEST study — 24 400
Waikato Breast Cancer Trust SNAC study 29 174 18 155
National Heart Foundation LIPID study — 140 000
Australasian Society of Thrombosis & Haemostasis ASPIRE study 57 455 —
National Institute for Clinical Excellence and National Health Service 
(UK)
Cochrane reviews — 35 631
UK Medical Research Council INIS study 107 205 75 782
University of Glasgow SCOTROC study — 61 380
Cardiac Society of Australia and New Zealand Scholarship — 29 406
Australasian Gastro-Intestinal Trials Group Cancer trials 531 256 297 617
Australian New Zealand Breast Cancer Trials Group Breast cancer trials 138 314 128 313
Gynecologic Oncology Group (US) Gynaecology trials 262 354 247 507
Merck and University of Oxford VICTOR study 214 106 —
Aventis Pharma Cancer trials (GOG 0201) 87 345 15 921
Aventis Pharma ATTAX study 95 796 148 277
Alphapharm ATTAX 2 study — 47 537
Bayer ASPIRE study 100 000 100 000
Bristol-Myers Squibb C0 17 study 746 843 933 541
Fournier Pharma FIELD study 7 596 760 7 662 416
Pﬁ zer DaVinci study 130 874 104 934
Roche (through AGITG) MAX  study — 302 745
Schering Plough CALYPSO study — 50 000
Various Donations, consultancies, 
workshops, student fees
322 723 251 282
TOTAL FUNDING  15 019 965 16 528 735
FUNDING IN 2004–2005
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THE CLINICAL TRIALS PROGRAM
The CTC has participated in more than 50 investigator-initiated, cooperative-group 
clinical trials, and coordinated some of the largest randomised trials initiated by 
Australian investigators (LIPID and FIELD studies, each with over 9000 patients). Over 
40 000 patients have been randomised to these trials. All clinical trials undertaken 
through the CTC are conducted strictly according to guidelines for clinical trials research 
and conduct, and are audited by regulatory authorities, sponsors and the CTC itself.
This history has been a basis for expansion and consolidation of the clinical trials 
program over the past few years. The continuing enhancement of the strategic 
directions of the program has three main ingredients.
•  First, the CTC instituted a matrix structure for the operation of clinical trials. The 
functions of project management, data management and site management, which 
are common to all trials, became discrete parts of the management structure. The 
three groups work to identify ways to increase eﬃ  ciency and eﬀ ectiveness and assist 
project managers and their teams to meet their objectives, which includes training 
staﬀ  in these functions. 
•  Second, the CTC continues to develop the generic, internet-based trial management 
system, Flexetrials; managers of CTC trials and other investigator-initiated trials can 
slot into this ready-made system of trials management.
•  Third, the CTC has maintained and strengthened ties with Australia-wide groups of 
investigators. Their potential to increase the number and relevance of their trials has 
recently been boosted by new grants for trials infrastructure.
Therefore the CTC ﬁ nishes 2005 with a solid basis for the prospect of new and better 
trials in 2006.
B U I L D I N G  C A PAC I T Y  F O R 
C L I N I C A L  T R I A L S  R E S E A R C H
BUILDING CAPACITY FOR CLINICAL TRIALS RESEARCH
THE CLINICAL TRIALS PROGRAM
Flexetrials: the internet-based clinical 
trials data and information network
Grant to develop internet-based 
systems
Oncology program initiatives 
COLLABORATIONS
Research collaborations
Biostatistics Collaboration of Australia
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The CTC: a national asset 
After steering many trials and helping others in theirs, the CTC has a critical mass of 
expertise in all aspects of trials design, conduct and analysis. Staﬀ  include clinical data 
managers, data systems specialists, clinicians, biostatisticians and other highly qualiﬁ ed 
and experienced professionals. It is well placed to apply this experience in sustaining 
new and better trials research.
Australian clinical trials programs are well established in the areas of cancer, vascular 
disease, diabetes and HIV. However, trials in many other areas are lacking, as is shown by 
the requests of groups approaching the CTC for help, the lack of high-level evidence for 
some new treatments and for the true value of new technologies, and the controversies 
in deﬁ ning optimal health care.
It is diﬃ  cult for an individual clinical researcher to launch a major clinical trial, and 
the cost to create and maintain a database to regulatory standards is high. The CTC 
has foreseen this need, and has resolved to help narrow the gaps in trials research by 
developing support systems for investigators. Grants received in 2005 are clearing the 
way toward making this possible.
Flexetrials: the internet-based clinical trials data and 
information network
Assisted by a Systemic Infrastructure Initiative grant from the Department of Education, 
Science and Training covering the years 2002 to 2004, the CTC has been developing 
Flexetrials, a generic internet-based clinical trials data and information network that 
meets national and international standards and which is currently being implemented 
in several national and international investigator-initiated trials.
Partners in this CTC-led project are the University of Queensland, Monash University, the 
University of Sydney and Phase Forward.
Flexetrials has been shaped with the speciﬁ c needs of public health clinical trials research 
in mind. The aim is to enable academic research institutions, among others, to conduct 
large multicentre national and international clinical trials in Australia more eﬃ  caciously, 
economically and eﬃ  ciently than has been possible so far. A particular focus of the CTC’s 
strategy in recent years has been to build and strengthen the infrastructure for clinical 
trials in areas of national interest.
New grants: a national internet-based trial support system
The CTC was fortunate in gaining an NHMRC Enabling Grant in 2005 to generate 
and mobilise clinical trials expertise and internet-based trials systems over the next 
ﬁ ve years. Grants from the Enabling Grants Scheme are intended to support excellent 
facilities or activities (to be available to Australian researchers) where there is a clearly 
demonstrated national need for them to underpin aspects of the national health and 
medical research eﬀ ort.
Wendy Hague
Clinical trials program director
Wendy Hague is clinical trials 
program director of the CTC 
and is primarily responsible for 
the successful conduct of the 
CTC’s clinical trials and ensuring 
that trials systems, procedures 
and methods are of the highest 
standard. 
»
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The grant will allow the CTC to continue and expand on the 
work already done in developing Flexetrials.
The next step is to bring about its use in the Australian research 
community so that it can fulﬁ l its purpose as a national resource 
for public-good, investigator-initiated trials in new areas of 
need. The system will be available to interested investigators to 
help them launch new high-quality clinical trials.
Priority will be given to trials:
•  evaluating surgery
•  evaluating new health technologies
•  assessing management strategies (such as multidisciplinary 
care, hospital in the home)
•  in alternative and complementary medicine
•  in supportive and palliative care, ambulance services and 
nursing care.
Funds from the new grant will complement the funding from 
government and industry for speciﬁ c trials and projects. 
The CTC already has strong links with Monash University, 
the University of Queensland and the George Institute for 
International Health. The CTC’s trials system will facilitate or 
foster collaborations with other major clinical trial centres in 
Australia wishing to undertake related activities.
Oncology program initiatives
The CTC houses the secretariats of the Australasian Gastro-
Intestinal Trials Group (AGITG) and the Australian and New 
Zealand Gynaecological Oncology Group (ANZGOG). Both are 
multidisciplinary clinical trials groups dedicated to improving 
the outcomes of patients through randomised phase III trials 
and novel phase II studies. They consist of clinical investigators 
working directly with patients in hospitals around Australia and 
elsewhere. These investigators know the needs of patients. They 
conceive new trials and conduct them, recruit patients to trials, 
hold scientiﬁ c meetings and participate in various educational 
activities.
The CTC plays a key role in the design, conduct and analysis of 
clinical trials undertaken by these groups.
Grant for the CTC’s work with 
cancer collaborative groups
In 2005, the CTC was successful in obtaining a grant from the 
Cancer Institute NSW to support the work of these groups over 
the next three years. It will be used to appoint expert dedicated 
oncology clinical trials staﬀ  to help conduct the next generation 
of trials, expand the clinical trials program and run an eﬀ ective 
quality-assurance program.
This program will also assist hospitals throughout New South 
Wales, including those in regional and rural areas, to participate 
in and conduct high-quality clinical trials run through these 
two groups. It will give cancer patients more opportunity 
to participate in clinical trials that answer important clinical 
questions about prevention, treatment and supportive care.
Support through this grant will enable the groups to, ﬁ rst, 
increase and strengthen their existing networks, second, initiate 
clinical trials to address important public health questions faster 
and, third, report the results sooner.
Grant for a clinical trials partnership in trial 
operations, biostatistics and audit
The CTC has successfully conducted or been an active 
participant in 38 cancer trials and has provided strategies or 
systems for patient recruitment, trial and data management, 
study coordination, information systems and randomisation in 
an environment of academic rigour and excellence. In addition, 
the CTC is a leader in biostatistical methodology and analysis.
With this background, the CTC has been recognised as a major 
partner in a new cooperative clinical trials program involving 
other New South Wales centres and groups: three years of 
funding from the Cancer Institute NSW was obtained in 
2005. The research program of this partnership will support 
investigator-initiated cancer clinical trials undertaken or 
coordinated in NSW and led or supported by the NSW Cancer 
Trials Group (CTG).
The CTC will contribute to clinical trials operations facilities 
(including the internet-based clinical trials database system); 
leadership, advice and support in biostatistics; and a quality-
assurance program, including auditing.
BUILDING CAPACITY FOR CLINICAL TRIALS RESEARCH
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BUILDING POTENTIAL THROUGH
COLLABORATION WITH OTHERS
Part of the CTC’s contribution to the national capacity in medical research is through its 
strong links with collaborative groups of widely dispersed investigators.
The focus in the past has been on evaluating strategies for treating and preventing 
the major causes of illness and premature death in Australia: cardiovascular disease, 
cancer and diabetes. Australasian collaborations of cardiologists and physicians are part 
of international eﬀ orts for treatment of acute myocardial infarction (the large trials of 
the international VIGOUR group, including the recent HERO-2 trial) and preventing 
coronary heart disease events (LIPID trial; see page 31). The recently completed FIELD 
trial (see page 26) evaluated prevention of cardiovascular events in diabetes. Many of 
the groups examining treatments for various cancers and taking part in international 
oncology studies have been set up and managed by the CTC.
More recently, new associations have been looking at less common, but very 
important, causes of death and disability: the ASPIRE group for deep-vein thrombosis 
(see page 16), and the neonatal groups for preventing disability in babies (see page 29).
The CTC also works closely with people in Australian universities in projects such as 
the internet-based trials infrastructure project and the Biostatistics Collaboration of 
Australia.
Much of the CTC’s research involves contracts with industry and government, because 
of the nature of the work (such as drug trials) and the scale of funding required. 
Partnerships that lead to better health outcomes are a long-standing part of the CTC’s 
tradition. »
Institution  Nature of institution Activity
ANZ Breast Cancer Trials Group (ANZ BCTG) Collaborative group for breast cancer trials: Australia, 
New Zealand 
International collaborations: International Breast Cancer Study 
Group (IBCSG), Breast International Group (BIG), International 
Breast Cancer Intervention Study (IBIS)
Statistical centre for group, including 
randomisation
ANZ Germ Cell Tumour Study Group (ANZ GCTG) Collaborative group for testicular cancer trials: 
Australia, New Zealand 
Coordinating centre
Australasian Gastro-Intestinal Trials Group (AGITG) Collaborative group for gastrointesinal cancer trials: Australia, 
New Zealand
International collaborations: NSABP (USA), ECOG (USA), 
EORTC (Europe)
Coordinating centre
Australasian Society of Thrombosis and Haemostasis Professional group undertaking thrombosis trials: 
Australia, New Zealand 
Coordinating centre
ANZ Gynaecological Oncology Group Collaborative group undertaking gynaecological cancer trials: 
Australia, New Zealand
International collaborations: Gynecological Cancer Intergroup 
(GCIG), International Gynaecological Cancer Intergroup (IGCI), 
Gynecologic Oncology Group (GOG)
Coordinating centre
Australian Clinical Trials Registry National register of Australian clinical trials Coordinating centre
»
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BUILDING CAPACITY FOR CLINICAL TRIALS RESEARCH
Institution  Nature of institution Activity
Australian universities University members of Biostatistics Collaboration of Australia Coordinating centre
Cochrane Collaboration Collaborative group undertaking systematic reviews of trial 
evidence: international
Editoral base of the Cochrane Breast 
Cancer Group
Cholesterol Treatment Trialists’ Collaboration (CTTC) Collaboration of clinical trial groups studying cholesterol 
treatments: Australia, New Zealand, United Kingdom, United 
States, Italy
Coordination of meta-analyses in 
heart disease
Department of Health and Ageing Government, Australia Provide assessments of new 
technologies and other research 
services
BCA: biostatistics education
FIELD Study Group Collaborative group for FIELD diabetes trial: Australia, New 
Zealand, Finland
Coordinating centre
Flinders Medical Centre, Australia Clinical and laboratory centre: Australia Co-collaborator on VIGOUR trials
LIPID Study Group Collaborative group for LIPID cholesterol-lowering trial: 
Australia, New Zealand 
Coordinating centre
TAIWAN
THE PHILIPPINES
AUSTRALIA AND NEW ZEALAND:
AGITG, ANZ BCTG, ANZ GERM CELL TRIALS GROUP,
ANZ GOG, ASPIRE, ACTR, BIOSTATISTICS COLLABORATION OF AUSTRALIA,
BOOST, ,
COCHRANE COLLABORATION, FIELD TRIAL, INIS TRIAL, LIPID TRIAL,
MSAC, SCOTROC, SNAC, AND VIGOUR GROUP: FMC, GLCC
CHOLESTEROL TREATMENT TRIALISTS’ COLLABORATION
EUROPE:
GASTROINTESTINAL TRIALS
( ESPAC, MRC, OCTC, WITH AGITG)
INIS TRIAL (NPEU)
EORTC,
BREAST CANCER TRIALS (ANZ BCTG, IBCSG, BCIRG)
CHOLESTEROL TREATMENT
TRIALISTS’ COLLABORATION (OXFORD)
FIELD TRIAL
COCHRANE COLLABORATION
SCOTROC TRIAL
VIGOUR GROUP
ASIA PACIFIC:-
AGITG
CLINICAL TRIALS EDUCATION
COLLABORATIONS
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Institution  Nature of institution Activity
National Cancer Institute of Canada Clinical Trials 
Group (NCIC CTG)
Trials research group Collaboration on cancer trials and 
meta-analysis
National Heart Foundation Nongovernment organisation , Australia Coordinate the LIPID trial for the NHF
National Perinatal Epidemiology Unit (NPEU), 
University of Oxford
Research institution: UK Co-collaborator on the INIS neonatal 
trial
NSW Cooperative Oncology Group Collaborative group: NSW Coordinate centre for the group
Oxford Clinical Trials Consortium (OCTC) Trials research group: UK Cancer trials
Prospective Pravastatin Pooling project Collaborative group: 
Australia, New Zealand, United States, Scotland
Coordinate centre
Royal Australasian College of Surgeons Professional society undertaking trials of surgery: 
Australia and New Zealand
Coordinating the SNAC trial in breast 
cancer with the RACS
VIGOUR group Collaborative group for trials of heart disease: 40 countries Data coordinating centre, Asia-Paciﬁ c 
Region; International statistical centre 
(HERO-2 trial)
NORTH AMERICA:
(NCIC, NSABP, ECOG)
ANZ BREAST CANCER TRIALS
(GCIG, US GOG, IGCI)
COCHRANE COLLABORATION
VIGOUR (DCRI, CCF, DCRIP, CVC)
GASTROINTESTINAL TRIALS
SOUTH AMERICA:
VIGOUR (LCC)
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Biostatistics Collaboration of Australia: 
meeting a national need for qualiﬁ ed biostatisticians
A postgraduate education program in biostatistics, delivered by distance means, is 
conducted by the Biostatistics Collaboration of Australia (BCA), a virtual training 
institution conducted from oﬃ  ces at the CTC. The collaboration comprises the 
University of Sydney, the Australian National University, Macquarie University, Monash 
University, the University of Melbourne, Newcastle University and the University of 
Queensland.
The BCA’s program ﬁ lls the gap between programs in public health and epidemiology 
and general statistics courses. By combining the best talents from around the country, 
this collaboration has developed a focused curriculum with a mission to provide 
Australia with well-trained professional biostatisticians. The courses deliver a sound 
mathematically based grounding in statistical methods with a strong emphasis on 
application to all areas of health and medical research.
The BCA was established in 2001 in response to a shortage of biostatistical expertise 
in Australia. It is an unincorporated consortium of leading biostatisticians from 
universities, government and industry. Representatives from these bodies comprise the 
steering committee, which administers the program.
In 2004, 142 students were enrolled in the program, with an increase to 172 in 2005. 
The group recently developed an additional elective unit, ‘Advanced clinical trials and 
meta-analysis’, which educates students to an advanced level in the statistical principles, 
issues and methods of the design and analysis of randomised controlled trials.
Erica Jobling
Executive oﬃ  cer, Biostatistics 
Collaboration of Australia
BUILDING CAPACITY FOR CLINICAL TRIALS RESEARCH
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BIOSTATISTICS COLLABORATION OF AUSTRALIA
STEERING COMMITTEE
Ms Caro Badcock, Covance Pty Ltd
Professor John Carlin, University of Melbourne
Dr Keith Dear, Australian National University
Professor Annette Dobson, University of Queensland
Ms Kate Brown, Department of Health and Ageing
Associate Professor Andrew Forbes, Monash University
Associate Professor Val Gebski, University of Sydney
Associate Professor Gillian Heller, Macquarie University
Associate Professor Ian Marschner, Pﬁ zer Pty Ltd
Dr Philip McCloud, Roche Products Pty Ltd
Ms Helen Moore, NSW Department of Health
Dr David Sibbritt, University of Newcastle
Associate Professor Judy Simpson, University of Sydney
CTC statisticians contribute to the Biostatistics 
Collaboration of Australia by developing, coordinating 
and teaching various subjects, including: ‘Principles of 
statistical inference’ – Adrienne Kirby, coordinator (left), 
‘Advanced clinical trials and meta-analysis’ – Stephane 
Heritier, coordinator (centre), and ‘Design of experiments 
and randomised controlled trials’ – Val Gebski, 
coordinator, with University of Newcastle (right).
As part of the BCA’s quality-assurance guarantees, the BCA was independently reviewed 
in August 2004. The review found that:
 The BCA has been successfully established as an outstanding multi-institutional 
system for developing, strengthening and sustaining Australia’s workforce of career 
biostatisticians. Through intensive coordination of expertise in seven universities 
and the use of distance education, the BCA is able to oﬀ er an educational program in 
biostatistics that is unique throughout Australia, and indeed the world, in terms of its 
depth and scope.
The NSW Department of Health employs trainees in a biostatistics oﬃ  cer training 
program. Students complete the Master of Biostatistics as part of this. Since 2001, 
six students have graduated 
with masters degrees from the 
University of Sydney.
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BRINGING AN EVIDENCE BASE TO DECISION MAKING AND POLICY: ACTR
CO 17: a new treatment for colorectal cancer that has 
progressed after chemotherapy
Cetuximab is a monoclonal antibody, which targets the epidermal growth factor 
receptor (EGFR), a protein on the surface of many cancer cells and some normal cells. 
When cetuximab binds to EGFR, the natural growth factors are barred from the receptor 
and therefore are unable to stimulate the cells. This leads to inhibition of cell growth and 
induction of cell death. Monoclonal antibodies are an important class of anticancer drug 
because they are very speciﬁ c. 
The CO 17 study is designed to determine the eﬀ ectiveness of cetuximab (Erbitux) 
on survival and quality of life in people with advanced colorectal cancer whose cancer 
has progressed after chemotherapy. It is sponsored by the AGITG in conjunction 
with the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). It is an 
investigator-initiated phase III study using cetuximab and best supportive care versus 
best supportive care alone for heavily treated metastatic colorectal cancer. 
The CTC has coordinated all clinical aspects of the trial in Australia, New Zealand and 
Singapore. 
Recruitment opened to the CO 17 trial in Australia in November 2003, with a target 
of 100 patients over two years. At the close of recruitment in August 2005, Australia 
had recruited 252 patients (from the international target of 500) to the trial. The trial 
received a positive report following an audit by Bristol-Myers Squibb US in 2005. Now 
in the follow-up stage, CO 17 remains one of the CTC’s most successful trials in terms of 
recruitment and coordination. The results will be presented at an international meeting 
early in 2007.
 
NEW TRIALS: CO 17 A D M X
Participants: 
Patients with heavily treated metastatic colorectal cancer who have a positive 
test for epidermal growth factor receptor (EGFR)
Study drug: cetuximab (Erbitux)
Primary outcome measure: survival
Recruitment: 252
Recruitment target: 500 (100 from Australia and New Zealand) 
Funding: Bristol-Myers Squibb
Cooperative group: NCIC, AGITG
PATIENTS WITH
EGFR-POSITIVE COLORECTAL CANCER
TREATED
TIME TO PROGRESSION, SURVIVAL, QUALITY OF LIFE
Best supportive careCetuximab + best
supportive care
ETHICS APPROVAL 
FOR ALL TRIALS
Each clinical trial is reviewed and 
approved by a central scientiﬁ c 
committee (NSW Shared Scientiﬁ c 
Assessment Committee), the 
University of Sydney Ethics 
Committee, and the ethics 
committees of each participating 
institution. 
CO 17
MAX
ASPIRE
BOOST II
STARTUP
2
N E W  T R I A L S
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treatment compared with 
a single drug for colorectal 
cancer
The MAX study is a new trial designed 
to determine the optimal low-toxicity 
regimen for a broad range of patients 
with advanced colorectal cancer. The 
study aims to improve the duration of 
survival without compromising quality 
of life.
The MAX study, which is sponsored 
by the AGITG and supported by Roche 
Products Pty Ltd, is an investigator-
initiated phase II–III study using monotherapy compared with combination treatment 
for previously untreated metastatic colorectal cancer. Capecitabine (Xeloda) and 
mitomycin C are standard chemotherapy treatments, and bevacizumab (Avastin) is a 
recombinant humanised anti-VEGF monoclonal antibody, which inhibits the growth of 
tumour blood vessels.
The CTC is coordinating all aspects of the trial, and the CTC’s internally developed 
internet-based data system will be used for collection of data from participating 
institutions in Australia, New Zealand and the United Kingdom, ensuring that processes 
for conduct of the trial are the best available. Recruitment began in June 2005.
MAX team
Sian Munro, Kate Wilson (trial coordinator) 
and Michelle Cummins 
(not pictured: Alyson France)
Participants: 
Patients with previously untreated metastatic colorectal cancer
Study drug: capecitabine, bevacizumab and mitomycin C
Primary outcome measure: progression-free survival
Recruitment target: 333
Recruitment: 104 from 26 Australian sites
Funding: Roche Products Pty Ltd
Cooperative group: AGITG
METASTATIC COLORECTAL CANCER
PROGRESSION-FREE SURVIVAL
Capecitabine
+ bevacizumab
+ mitomycin C
Capecitabine
+ bevacizumab
Capecitabine
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Aspirin may prevent recurring 
deep-vein thrombosis: ASPIRE study
Patients who have had deep-vein thrombosis or pulmonary embolism are at risk of 
recurrence after stopping warfarin treatment. Long-term warfarin prevents recurrence, 
but may cause signiﬁ cant bleeding. Preventing recurrence with low-dose aspirin is being 
investigated in the ASPIRE (Aspirin to prevent recurrent venous thromboembolism) 
study. Low-dose aspirin is a simple, inexpensive, and widely practicable treatment which 
could potentially help thousands of patients.
ASPIRE is a multicentre, randomised double-blind placebo-controlled trial examining 
the eﬃ  cacy and safety of low-dose aspirin after initial anticoagulation therapy to 
prevent recurrent venous thromboembolism.
After a pilot study which began in 2003, recruitment of sites and patients began 
in 2004. The target is 1500 participants in Australia and New Zealand and 3000 
internationally. 
ASPIRE is the ﬁ rst trial to use the CTC’s internet-based trials management system, 
Flexetrials. 
***
ASPIRE and the WARFASA study are 
joining in the prospectively designed 
meta-analysis, INSPIRE 
(see page 44). 
Participants: 
People who have had a ﬁ rst episode of unprovoked proximal deep-vein 
thrombosis or pulmonary embolism and completed anticoagulant treatment.
Study drug: acetylsalicylic acid (aspirin)
Main outcome measures:
• symptomatic venous thromboembolism or fatal pulmonary embolism
• total vascular events (cardiovascular death, symptomatic venous 
thromboembolism, myocardial infarction or stroke) 
• net clinical beneﬁ t (death, major vascular event or major bleeding)
Recruitment target:  3000
Recruitment: 241
Funding: NHMRC, Bayer, Australasian Society of Thrombosis and Haemostasis 
(ASTH)
Cooperative group: ASTH
Rebecca Mister
ASPIRE study manager
NEW TRIALS: ASPIRE AND BOOST II
DEEP-VEIN THROMBOSIS OR PULMONARY EMBOLISM
TREATED WITH HEPARIN AND WARAFIN
THROMBOSIS OR EMBOLISM
PlaceboAspirin
TRIAL MONITORING
Arising from the policy of having 
common trials systems that apply 
to all CTC trials, generic procedures 
for trial monitoring have been 
developed. Monitoring activities 
expanded during 2004–2005, 
with the strengthening of generic 
CTC monitoring plans, on-site 
monitoring procedures and the 
training of staﬀ  as dedicated site 
monitors. 
Staﬀ  of the AGITG CO 17 and MAX 
trials and the ANZGOG Calypso trial 
have recently been trained in site 
monitoring. 
Monitoring processes will continue 
to be adapted to internet-based 
data-capture case-report forms 
which are also used in the ASPIRE 
and BOOST II trials. This allows CTC 
staﬀ  to view data on line before 
visiting sites. 
2
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BOOST II (Beneﬁ ts of oxygen saturation targeting): 
ﬁ nding the right level of oxygen for newborn babies
Each year in Australia, about 850 children born before 28 weeks of gestation are 
admitted to neonatal intensive care units and about 75% are discharged home alive. 
These very premature infants have a higher than normal risk of chronic lung disease, 
poor growth, respiratory illness, visual deﬁ cits, cerebral palsy, sensorineural disability 
and cognitive impairment. They account for most of the costs of neonatal intensive 
care.
The most common therapy is oxygen. It has been associated with better survival and 
less disability. However, premature infants are highly sensitive to the harmful eﬀ ects of 
oxygen. Levels of oxygen in a lower range may increase heart abnormalities and lung 
disease and impair brain development; levels in a higher range may increase blindness 
and lung disease, and impair brain development. 
Currently, the best level of oxygenation is not known. A wide spectrum of opinion 
and practice exists. BOOST II is one of several large trials around the world which will 
ascertain which of two currently used ranges of oxygen saturation is better in terms 
of net beneﬁ t. Infants will be randomised to a target oxygen saturation of 85–89% 
or to a target of 91–95%. These levels are lower than those of the ﬁ rst BOOST trial 
(91–94% and 95–98%) in which the higher saturation showed no beneﬁ t.
The trial is currently about to begin randomisation. It will enrol 1200 very premature 
babies from the major hospitals in Australia and will contribute to a worldwide 
prospective meta-analysis of data from about 5000 babies.
This trial will answer important questions about the beneﬁ ts and risks of higher 
compared with lower oxygen levels, and will improve the care of thousands of 
Australian children and millions more worldwide. 
Alpana Ghadge 
BOOST II study manager
Blinding of clinical staﬀ  in BOOST II
BOOST II has a novel blinding method successfully used in the ﬁ rst BOOST trial.
The oximeters, which display oxygen saturation in the infant’s blood, will be 
calibrated to display a value 3% higher than the actual saturation in infants in 
the low-oxygen group, or 3% lower than the actual saturation in infants in the 
high-oxygen group. 
The high-oxygen group will have an actual target range of 91–95% and the 
low-oxygen group an actual target range of 85–89%. Staﬀ  will aim for an 
oxygen saturation of 88–92% for all and remain unaware of the real saturation 
range.
Pulse oximeter
The pulse oximeter is a machine about the 
same size as a DVD player, kept on a shelf near 
the baby. These pictures show a pulse oximeter 
and its display.  In this case, the baby’s oxygen 
saturation reading is 99% and heart rate is 81.
N
EW
 TRIA
LS
Participants: 
Neonates born before 
28 weeks gestation
Study drug: Supplementary 
oxygen to 85–89% saturation or 
91–95% saturation from the day 
of birth until the baby breathes air
Primary outcome measure: 
Death or survival with major 
disability at two years
Main secondary 
outcome measures: 
• retinopathy of prematurity
• chronic lung disease
Recruitment target: 1200
Funding: NHMRC in Australia 
(Health Research Council in 
New Zealand)
Cooperative group: 
BOOST II Investigators
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Searching for the best way to control heart rhythm after 
heart surgery
Atrial ﬁ brillation, a fast irregular rhythm of the heart, is the most common cause of 
delay in discharge from hospital after cardiac surgery and the most common reason 
for readmission to hospital. The occurrence of postoperative atrial ﬁ brillation has 
been linked to stroke, delirium and neurocognitive decline. There is no consensus on a 
preventive strategy. Surgical techniques are continually improving and beta-blockers 
are now routinely being used after surgery to reduce atrial ﬁ brillation. Despite this, 
postoperative atrial ﬁ brillation is still increasing. 
STARTUP (Stop atrial ﬁ brillation after revascularisation using prevention) was 
commenced as a pilot study to test two of the most promising treatments to prevent 
atrial ﬁ brillation: biatrial overdrive pacing for 96 hours after the operation, and 
amiodarone, an antiarrhythmic drug, before and after the operation. Biatrial pacing uses 
temporary wires placed during the surgery at the heart’s right atrium and left atrium. 
The pacemaker is set at ten beats per minute above the person’s intrinsic heart rate 
(“overdrive pacing”) to suppress atrial ectopic beats.
The preliminary results of the pilot study conﬁ rm the high incidence of atrial ﬁ brillation 
after surgery: 43% of patients had atrial ﬁ brillation, highlighting the need for a deﬁ nitive 
prevention strategy.
David Burgess was awarded a scholarship from the Cardiac Society of Australia and New 
Zealand for his research on STARTUP in 2005. The principal investigator is Professor 
Anthony Keech.
David Burgess 
Coinvestigator and coordinator 
of the STARTUP study
Participants:  
People aged over 55 years at risk of atrial ﬁ brillation after cardiac surgery
Design: two-by-two factorial
Interventions: 
• biatrial overdrive pacing
• amiodarone, 10 mg/kg per day for ﬁ ve days before and 
ﬁ ve days after operation
Primary outcome measures: atrial arrhythmia for more than 
ﬁ ve minutes requiring treatment
Recruitment: 70
Funding: NHMRC Program Grant to seed new research
Preparing for a trial with 
a meta-analysis
A review of existing trials can 
be a starting point for a new 
trial. Going through this process 
ensures that the new trial is not 
a duplicate and does not look 
for answers that have already 
been found. A preliminary 
meta-analysis of the available 
evidence supports the reasons for 
undertaking the trial and helps 
the investigators to reﬁ ne the 
hypotheses.
It is unscientiﬁ c and unethical 
to embark on new research 
without ﬁ rst analysing 
systematically what can be 
learned from existing research 
—  Iain Chalmers
STARTUP has been aided by 
the STARTUP investigators’ 
meta-analysis of trials concerned 
with ways of preventing 
postoperative atrial ﬁ brillation. 
The meta-analysis showed 
that the interventions were 
eﬀ ective in preventing monitor-
recorded atrial ﬁ brillation and 
that a multicentre trial of the 
most eﬀ ective strategies was 
warranted to ascertain the net 
clinical beneﬁ t. These results were 
presented in 2005 and will be 
published in 2006.
NEW TRIALS: STARTUP
CARDIAC SURGERY PATIENTS
OCCURRENCE OF ATRIAL FIBRILLATION FOR
>5 MIN REQUIRING TREATMENT
Amiodarone Placebo
Atrial pacing
Amiodarone Placebo
No pacing
2
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BREAST CANCER
GASTROINTESTINAL CANCER
GYNAECOLOGICAL CANCER
Established cancer trials continue the CTC’s tradition
The CTC has a strong record of working with cancer cooperative groups, clinical trial 
networks and other organisations (including the pharmaceutical industry), locally 
and internationally, in the conduct of investigator-initiated clinical trials 
contributing to the welfare of patients and public health.
The oncology program has played a key role in establishing and operating some of 
these: for example, the AGITG (see page 21) and the ANZGOG (see page 24). The 
groups have international links with overseas and international collaborative 
groups, including the National Surgical Adjuvant Breast and Bowel Project 
(NSABP), the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), 
the European Organisation for Research and Treatment of Cancer (EORTC), the 
Oxford Clinical Trials Oﬃ  ce (OCTO), the Gynaecologic Cancer Intergroup (GCIG), the 
Gynecologic Oncology Group (GOG) and the Medical Research Council (MRC) (see 
page 10). These alliances have resulted in researchers from sites in Australia and 
New Zealand successfully recruiting patients to international trials, including: C07, 
ESPAC-3, advanced GIST, CO 17 gastrointestinal cancer trials, and Calypso and GOG 
199 gynaecology trials. The CTC is responsible for site activation, recruitment, 
monitoring, audit and other trial activities.
The CTC is the randomisation and statistical centre for the Australian New Zealand 
Breast Cancer Trials Group (ANZ BCTG), which works with the International Breast 
Cancer Study Group (IBCSG). The CTC has also been involved in quality-of-life and 
cost-eﬀ ectiveness studies for this group.
With the rapid development of new therapies and a greater emphasis on biological 
mechanisms of action, collaboration on such trials is now a critical component of 
success in answering important questions. A beneﬁ t of such enterprises is faster 
access of patients to novel therapies. As well, Australian clinicians, researchers and 
patients can contribute to the continued development of new and improved 
treatments in a global environment.Oncology program executive
Wendy Hague, Burcu Cakir, Martin Stockler,
 John Simes (not pictured: Kathleen Scott, 
Corona Gainford and Val Gebski)
 NHMRC CLINICAL TRIALS CENTRE: 2004–2005 RESEARCH REPORT 19
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A popular trial to reduce the side-eﬀ ects 
of breast cancer surgery
The SNAC (Sentinel node biopsy versus axillary clearance) trial, which started recruiting 
patients in 2001, is the ﬁ rst large trial of surgical treatment of breast cancer in 
Australasia. Its aim is to ascertain whether the outcomes after biopsy of a sentinel lymph 
node are as good as the outcomes after axillary node clearance, the standard procedure.
The trial arose from a realisation that lymphoedema (pain and swelling in the arm), a 
common complication of breast lymph node surgery, was a major concern of women 
with breast cancer. Removal of sentinel nodes is much less invasive and may be much 
less damaging than removal of many lymph nodes.
The trial is expected to provide important information on the eﬀ ects of axillary surgery 
and the quality of life of women having breast cancer surgery.
Recruitment was completed in May 2005, over a year earlier than projected, with 
1088 patients enrolled. The success of recruitment was attributed to the interest of 
women and clinicians in the new procedure, the support of cancer organisations, the 
workshops and newsletters provided by the management team, and the fact that the 
Royal Australasian College of Surgeons (RACS) facilitated the collaboration of the 
centres. Patients were recruited from a broad range of small and large, and public and 
private, centres. Before hospitals could take part in the trial, their surgeons took part 
in workshops where they developed their skills in discussing trials with patients and 
obtaining consent. Each centre was ﬁ rst accredited by a management committee review 
of 20 consecutive cases of the sentinel node biopsy procedure, including operative and 
nuclear medicine techniques. 
The trial’s measured outcomes include both objective and self-reported quality-of-life 
measures. Patients are followed up at one, six and twelve months, and then annually.
SNAC 2
SNAC 2 is an extension of the SNAC 1 trial, and is expected to begin recruitment early 
in 2006. The expected number of participants is 1012. Its aim is to determine the safety 
and eﬀ ectiveness of sentinel-node-based management of the axilla for women with 
primary breast cancer. SNAC 2 has extended  the eligibility criteria of SNAC 1 to include 
women with multiple primary tumours in the same breast and women with tumours 
larger than 3 cm. The primary endpoint for this trial is the risk of recurrence of the 
tumour, particularly local axillary recurrence. Also, the diagnostic accuracy of sentinel 
node biopsy is a particular focus of the trial.
Participants (SNAC 1): 
Women with a single primary 
breast tumour <3 cm in 
diameter in whom disease 
staging was indicated
Main outcome measures: 
Early axillary morbidity, 
lymphoedema, axillary tumour 
recurrence, survival, disease-
free survival, use of adjuvant 
therapies, number of surgical 
episodes, days in hospital
Recruitment: 1088
Funding: Medical Beneﬁ ts Fund, 
Commonwealth Department 
of Health and Ageing, National 
Breast Cancer Foundation, 
National Health and Medical 
Research Council
Cooperative group: 
Royal Australasian College 
of Surgeons (RACS)
EARLY BREAST CANCER
DISEASE RECURRENCE, ARM VOLUME, QUALITY OF LIFE
Delayed axillary surgery
Sentinel node biopsy
(AC arm)
Sentinel node biopsy
(SNB arm)
Immediate
axillary clearance
Unsuccessful-ve +ve
Xanthi Coskinas 
SNAC study coordinator
3
IMPROVING SURVIVAL AND QUALITY OF LIFE IN CANCER: SNAC AND AGITG
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Trials of the Australasian Gastro-Intestinal Trials Group
The CTC is the coordinating centre for the Australasian Gastro-Intestinal Trials Group 
(AGITG), which has a network of clinical investigators across Australia and New Zealand. 
Since it began in 1991, the AGITG has participated in or conducted 24 gastrointestinal 
cancer trials and recruited more than 1250 patients to investigator-initiated trials, trials 
that in most cases would not, and often could not, be conducted by industry. The CTC’s 
participation in the diﬀ erent trials ranges from provision of single services, such as 
randomisation or statistical analysis, to complete management of the trials.
The CTC coordinated an AGITG trial investigating whether it is better to start 
chemotherapy on diagnosis of colon cancer, when patients still feel well, or to wait until 
they have symptoms. The results, published in the British Journal of Cancer, showed that 
delayed treatment did not aﬀ ect the patients’ survival, and allowed them better quality 
of life in the meantime. The study was analysed and reported as part of a meta-analysis 
(see page 42). 
The CTC provided data management and statistical services to the AGITG and the 
Trans-Tasman Radiological Oncology Group (TROG) for the trial on whether adding 
chemoradiotherapy to surgery helped people with cancer of the oesophagus. The 
trial was completed, and results were published in 2005 in Lancet Oncology. The 
chemotherapy was safe and reduced the growth of the tumours, but did not necessarily 
improve survival.
Another completed trial, a pilot study of the use of octreotide in advanced 
hepatocellular carcinoma, has also been completed and will be published soon.
Some AGITG trials
Danielle Miller 
Associate program manager for 
the AGTIG trials
Trial Participants Interventions Main outcome 
measures 
Status 
Da Vinci: 
Phase III trial of irinotecan versus irinotecan + De 
Gramont schedule 5-ﬂ uorouracil and folinic acid in 
patients with previously treated metastatic colorectal 
cancer (AG0103CR) 
People with previously 
treated metastatic 
colorectal carcinoma 
• irinotecan + 
5-ﬂ ourouracil + 
leucovorin 
• irinotecan 
• objective tumour 
response
• toxicity
• safety
• progression-free 
survival
• quality of life
• overall survival
The trial was planned 
as a 2-way trial also 
looking at the role of 
celecoxib in reducing 
side eﬀ ects, but 
these arms have been 
suspended. 
Recruitment target: 300 
Recruitment:  9
ATTAX: 
Phase II study evaluating a weekly schedule of 
docetaxel with cisplatin and 5-ﬂ uorouracil or 
capecitabine (AG0603G) 
Patients with advanced 
oesophageal or gastric 
cancer 
• docetaxel, cisplatin, 
5-ﬂ uorouracil
• docetaxel, 
capecitabine 
• tumour response Recruitment target: 100 
Recruitment: 75
ATTAX2: 
Phase II study of cetuximab plus docetaxel in 
docetaxel-refractory patients with EGFR-positive 
cancer (AG0603G EXT) 
Patients with advanced 
oesophageal or gastric 
cancer 
• cetuximab + 
docetaxel 
• tumour response Recruitment target: 35 
Recruitment: 8
GOFURTGO: 
Phase II study of ﬁ xed dose rate gemcitabine– 
oxaliplatin integrated with concomitant 5-ﬂ uorouracil 
and radiotherapy to treat localised pancreatic cancer 
(AG0503P) 
Patients with localised 
pancreatic cancer 
• radiotherapy, 
gemcitabine and 
oxaliplatin 
• tumour 
• response safety 
Recruitment target: 45 
Recruitment: 10
»
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Trial Participants Interventions Main outcome 
measures 
Status 
MAX: 
Phase II–III study to evaluate the role of Mitomycin 
C (mitomycin), Avastin (bevacizumab) and Xeloda 
(capecitabine) in patients with untreated metastatic 
colorectal cancer (AG0501CR) 
Patients with previously 
untreated metastatic 
colorectal cancer 
• capecitabine
• capecitabine + 
bevacizumab
• capecitabine + 
bevacizumab + 
mitomycin
• toxicity
• response
• progression-free 
survival
Recruitment target: 333 
Recruitment: 104 
ABC: 
Phase II trial of gemcitabine in ﬁ xed dose rate infusion 
compared with cisplatin in patients with biliary tract 
carcinoma (AG0403BT) 
Patients with 
inoperable biliary tract 
carcinomas 
• gemcitabine 
• cisplatin 
• tumour response
• safety 
Recruitment target: 45 
Recruitment: 25
ESPAC-3: 
European study of adjuvant chemotherapies in 
resectable pancreatic cancer 
Patients with 
histologically proven 
cancer of the pancreas 
who have undergone 
surgery 
• surgery + 
5-ﬂ uorouracil + 
leucovorin 
• gemcitabine 
• surgery 
• survival 
• progression-free 
survival 
Recruitment target: 150
Recruitment: 74 
C06: 
Oral uracil and ftorafur + leucovorin compared with 
5-ﬂ uorouracil + leucovorin for patients with stages II 
and III carcinoma of the colon 
Patients with 
stage II or stage IIII 
adenocarcinoma and 
no metastatic disease 
and a life expectancy 
of at least ten years 
(excluding diagnosis of 
cancer)  
• 5-ﬂ uorouracil + 
leucovorin 
• UFT (tegafur and 
uracil) + leucovorin 
• disease-free survival
• survival 
• quality of life
• prognostic 
signiﬁ cance of genetic 
and biologic markers 
Closed
Recruitment: 11
C07: 
5-ﬂ uorouracil + leucovorin compared with 
5-ﬂ uorouracil + oxaliplatin for the treatment of 
patients with stages II and III carcinoma of the colon 
Patients with resected 
stage II or stage III 
colon carcinoma 
• 5-ﬂ uorouracil + 
leucovorin
• 5-ﬂ uorouracil + 
oxaliplatin
• disease-free survival
• survival
Closed
Recruitment: 134
CO 17: 
Phase III study of cetuximab and best supportive care 
versus best supportive care in patients with pretreated 
metastatic epidermal-growth-factor-receptor 
(EGFR)-positive colorectal carcinoma 
Patients with 
pretreated metastatic 
colorectal cancer with 
positive EGFR 
• cetuximab + 
supportive care
• supportive care
• survival
• time to progression
• response
• quality of life
Recruitment target: 100 
Recruitment: 252 
EORTC 62005: 
Phase III study of two diﬀ erent doses of imatinib 
mesylate in patients with CD117-expressing 
metastatic or unresectable gastrointestinal stromal 
tumour 
Patients with 
metastatic 
gastrointestinal stromal 
tumour 
• imatinib 2X daily 
• imatinib 1X daily 
• progression-free 
survival 
• survival 
• tumour response 
Closed 
Recruitment: 116
EORTC 40983: 
Phase III reoperative and postoperative chemotherapy 
with oxaliplatin + 5-ﬂ uorouracil + leucovorin versus 
surgery alone in resectable liver metastases from 
colorectal origin: phase III study 
Colon cancer with liver 
metastases 
• 5-ﬂ uorouracil 
+ leucovorin + 
oxaliplatin
• surgery 
• progression-free 
survival 
• survival 
Closed 
Recruitment: 35
EORTC 62024: 
Gastrointestinal stromal tumors (GIST) expressing 
KIT receptor: adjuvant imatinib mesylate (Glivec) 
versus no further therapy after surgery
Patients with resected 
gastrointestinal stromal 
tumour
• imatinib • overall survival
• relapse-free survival
• relapse-free interval
Recruitment target: 8 
Recruitment: 6
3
IMPROVING QUALITY OF LIFE IN CANCER: AGITG AND ANZ BCTG
Some  AGITG trials (continued)
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Trials of the Australian New Zealand 
Breast Cancer Trials Group 
The Australian New Zealand Breast Cancer Trials Group (ANZ BCTG) has an agreement 
with the CTC to provide an ANZ BCTG randomisation and statistical centre which 
undertakes clinical trials registration, randomisation and statistical services.  Quality-of-
life and economics substudies are also under the remit of activities conducted at the CTC 
in collaboration with the ANZ BCTG operations oﬃ  ce in Newcastle led by Professor John 
Forbes.
This service was formally reviewed in 2005 by invited international clinical triallists: 
Eleanor McFadden, expert data manager experienced in international multisite clinical 
trials and Mark Buyse, a biostatistican well known to cancer trials. The review revealed 
the high level of commitment and collaboration between the two centres, resulting in 
an excellent level of service to the sites in Australia and New Zealand recruiting patients 
to breast cancer trials.
Some ANZ BCTG trials
Trial Participants Interventions Main outcome 
measures
Status
ANZ O2P2 (IBIS II): 
International multicentre trial of anastrozole vs 
placebo in postmenopausal women 
1. Postmenopausal 
women at risk of breast 
cancer
2. Postmenopausal 
women with hormone-
sensitive ductal 
carcinoma in situ
• tamoxifen
• anastrozole
• breast cancer Opened July 2005
Recruitment: 
1000 (international)
18 (Australia and New 
Zealand)
International target: 
10 000
IBCSG 22: 
Low dose cytotoxics as anti-angiogenesis 
treatment following adjuvant induction 
chemotherapy 
Women with oestrogen-
receptor-negative and 
progesterone-receptor-
negative early breast 
cancer
• 12 months of 
low-dose oral 
chemotherapy
• breast cancer 
recurrence
Opened March 2002. 
Recruitment: 
307 (international), 
10 (Australia 
and New Zealand)
International target: 
900
ATLAS: 
Adjuvant tamoxifen: longer against shorter
Patients with previous 
breast cancer
• tamoxifen • mortality
• nonfatal events
Closed in 2005. 
Recruitment: 
784 (Australia and New 
Zealand)
ANZ 0001: 
Phase II trial to evaluate oral capecitabine vs 
cyclophosphamide, methotrexate and 
5-ﬂ uorouracil (CMF) for advanced breast cancer
Patients with advanced 
breast cancer and no 
previous chemotherapy
• intermittent 
capecitabine
• continuous 
capecitabine
• standard CMF
• time to progression
• tumour response
• quality of life
Closed in 2005
Recruitment:  324
ANZ 0201 (TIBER): 
Phase II trial of ZD1839 (Iressa) in patients with 
hormone-insensitive or hormone-resistant 
inoperable breast cancer
Advanced hormone-
resistant or receptor-
negative breast cancer, 
or progression after two 
hormone therapies
• ZD1839 (Iressa) 
daily until disease 
progression
• clinical beneﬁ t Closed to recruitment in 
September 2004 after 
interim assessment 
showed a low rate of 
clinical beneﬁ t.
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Trials of the Australia New Zealand 
Gynaecological Oncology Group
The Australia New Zealand Gynaecological Oncology Group (ANZGOG) works to 
improve outcomes for women with gynaecological cancer via a coordinated approach 
to clinical trials research. The group is a member of the international Gynecologic 
Cancer Intergroup (GCIG) and the United States Gynecologic Oncology Group (GOG), 
and is also linked with the Australian Ovarian Cancer Study, a large translational and 
epidemiological study funded by the US National Cancer Institute (NCI).
In late 2005 the CTC started the Australian and New Zealand participation in two 
international trials of ovarian cancer. The chief investigator of both trials is Associate 
Professor Paul Vasey.
Calypso (Caelyx in platinum-sensitive ovarian patients), a trial of the Gynecologic Cancer 
Intergroup, is comparing liposomal doxorubicin (Caelyx) + carboplatin and paclitaxel + 
carboplatin as a second-line treatment for patients with epithelial ovarian cancer in late 
relapse. Funding is provided by the lead international group in France (Gineco).
SCOTROC4 is one of a series of trials of the Scottish Gynaecological Cancer Trials Group 
(SGCTG). This trial will examine whether a dose-escalation strategy for carboplatin 
chemotherapy is better than a ﬁ xed dose for women with ovarian, or related, cancers. 
The CTC will receive funds from a successful multistate Cancer Council grant to support 
recruitment at sites through per-patient payments, as well as central funding from the 
Scottish group. 
Kathleen Scott, oncology program co-manager, is responsible for ANZGOG trials.
Julie Martyn
Associate program manager 
for ANZGOG trials
Reﬁ ning chemotherapy regimes for ovarian cancer
The standard care for ovarian cancer is surgery followed by chemotherapy with 
a combination of a platinum and taxane (such as carboplatin and paclitaxel). 
More than half the patients with advanced ovarian cancer develop recurrent 
disease within a few months. The need for eﬀ ective but minimally toxic 
chemotherapy treatments has led researchers to seek new agents and new 
combinations of drugs and to reﬁ ne the dosing regimens.
Current trials are comparing:
•  diﬀ erent dosages of the same drug (SCOTROC4)
•  new combinations (GOG 182)
•  new forms of drugs (Calypso, in which the new drug is doxurubicin in 
polyethylene glycol (PEG)-coated liposomes giving it a longer half-life and 
better penetration of the tumour).
IMPROVING QUALITY OF LIFE IN CANCER: ANZGOG
Report-Shaker[recover].indd   Sec4:24 05/12/2006   06:09:38
 NHMRC CLINICAL TRIALS CENTRE: 2004–2005 RESEARCH REPORT 25
IM
PRO
V
IN
G
 SU
RV
IVA
L A
N
D
 Q
U
A
LITY O
F LIFE IN
 CA
N
CER
Trial Participants Interventions Main outcome 
measures
Status
SCOTROC4: 
Multicentre randomised trial of carboplatin 
ﬂ at dosing vs intrapatient dose escalation in 
ﬁ rst-line chemotherapy of ovarian, fallopian 
tube and primary peritoneal cancers
Women with ovarian, 
fallopian tube or 
peritoneal carcinoma for 
whom platinum–taxane 
therapy is unsuitable
• 6 cycles carboplatin, 
ﬁ xed dose
• 6 cycles carboplatin 
with changes to 
dose depending on 
neutrophil count
• disease progression Recruitment target: 
1300 (international), 
150 (Australia 
and New Zealand)
Open to recruitment
CALYPSO: 
Caelyx in platinum-sensitive ovarian patients
Women whose disease 
has progressed after 
treatment
• pegylated liposomal
doxorubicin + 
carboplatin
• paclitaxel + 
carboplatin
• disease-free survival Recruitment target: 
864 (international), 
125 (Australia 
and New Zealand)
Open to recruitment
ANZGOG 0201: 
Phase II trial of weekly docetaxel for patients 
with relapsed ovarian cancer
Women whose disease 
has progressed after 
treatment
 • docetaxel (Taxotere) • toxicity
• time to progression
• overall survival
Closed.
Final publication in 
preparation
GOG 182: 
Phase III randomised trial of paclitaxel + 
carboplatin versus triplet or sequential doublet 
combinations in patients with epithelial ovarian 
or primary peritoneal carcinoma
Women with advanced 
stage (stage III or IV) 
primary ovarian or 
peritoneal cancer
• gemcitabine or 
topotecan with 
carboplatin 
(doublet therapy) 
or carboplatin + 
paclitaxel 
(triplet therapy).
• survival
• toxicity
• disease-free survival
Recruitment: 
3882 (international), 
183 (Australia 
and New Zealand)
In follow-up
GOG 199: 
Prospective study of risk-reducing 
salpingo-oophorectomy and longitudinal 
CA-125 screening among women at 
increased genetic risk of ovarian cancer
Women aged >30 at risk 
of ovarian cancer.
• choice of preventive 
surgery
• screening
• survival
• quality of life
Recruitment: 
2400 (international), 
100 (Australia 
and New Zealand)
Open to recruitment
HOSTT (ANZGOG 0401): 
Phase II study to evaluate the impact of 
maintaining haemoglobin levels above 
120 g/L vs over 100 g/L  
 
Women with previously 
untreated cancer of 
the cervix receiving 
concurrent cisplatin and 
radiation therapy
• Red cell transfusion • diﬀ erent haemoglobin 
levels
• progression-free 
survival 
Recruitment:
100 in pilot study 
400 in stage 2 (Australia, 
New Zealand and Taiwan)
Open to recruitment in 
2006 
ANZGOG trials
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Preventing cardiovascular disease in diabetes
The FIELD study, Australia’s largest clinical trial, was completed in 2005, and the main 
results were published in The Lancet. FIELD—Fenoﬁ brate Intervention and Event 
Lowering in Diabetes—aimed to ﬁ nd out whether treatment with fenoﬁ brate, a potent 
modiﬁ er of blood lipid levels, would reduce the risk of fatal coronary heart disease in 
people with type 2 diabetes. The trial recruited 9795 patients and followed them up over 
an average of ﬁ ve years.
Fenoﬁ brate raises blood levels of high-density lipoprotein cholesterol (HDL, the 
protective cholesterol form) and reduces low-density lipoprotein cholesterol (LDL) 
and triglycerides. Whether this physiological beneﬁ t is translated into better health and 
survival for diabetes suﬀ erers was the general question of the trial. Speciﬁ cally, it asked 
whether fenoﬁ brate treatment would lower the risk of fatal coronary heart disease or 
myocardial infarction.
Fenoﬁ brate did not reduce deaths from heart disease. It did, however, reduce myocardial 
infarction by about a quarter. Patients in the fenoﬁ brate group were less likely to 
have revascularisation (bypass grafting or procedures to remove arterial blockages) of 
coronary and other arteries. Fenoﬁ brate beneﬁ ted patients in reducing the need for 
procedures to repair blood vessels, such as laser treatments for eyes. The total number 
of cardiovascular disease events was statistically signiﬁ cantly lower (by 11%) in the 
fenoﬁ brate-allocated patients; those without any history of cardiovascular disease and 
younger patients were more likely to beneﬁ t from fenoﬁ brate.
FIELD TRIAL
CTC staﬀ  who worked for FIELD, with 
representatives of Fournier Pharma, 
at the ﬁ nal investigators’ meeting in 
November 2005.
P R E V E N T I N G  H E A R T  D I S E A S E
4
PREVENTING HEART DISEASE
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Many patients in the trial started taking statin lipid-lowering drugs over the ﬁ ve years 
of follow-up, presumably in response to their cholesterol levels. This was anticipated 
in the trial design, although the actual rates of statin use were higher than expected, 
particularly in the group of patients with prior cardiovascular disease. By the close of the 
trial, 32% in the placebo group and 16% in the fenoﬁ brate group were taking statins. 
The diﬀ erence between the groups in statin use may have masked an extra 5–7% eﬀ ect 
of fenoﬁ brate, and thus at least partly explained why the observed eﬀ ect of fenoﬁ brate 
was less than expected.
Analysis of data on the safety of the study drug showed that patients allocated 
fenoﬁ brate did not discontinue their medication more often than those allocated 
placebo. Fenoﬁ brate was not related to any speciﬁ c cause of death or to any speciﬁ c 
harm, such as cancers.
In 2005, FIELD was audited to assess the scientiﬁ c quality and accuracy of selected 
areas and data ﬁ elds relevant to the main trial conclusions. Twenty-seven randomly 
selected sites were visited for site auditing. The examination of trial-related activities 
and documents aimed to verify that the data were recorded, analysed and accurately 
reported according to the protocol, the sponsor’s standard operating procedures, Good 
Clinical Practice guidelines and applicable regulatory requirements. The auditors checked 
medical records for whether patients met the inclusion criteria for the trial, whether their 
medical history was properly documented and whether there were any undocumented 
events. The auditors’ review of the central management of the trial examined all aspects 
of data collection and recording, with additional probing of the accuracy of cancer 
reporting. There was a very low rate of errors in both site and internal audits, leading to 
a high level of conﬁ dence in the integrity of data and results. Under-reporting of events 
from the hospitals was rare and not related to randomised treatment.
People
FIELD has been internationally managed by a team at the CTC, headed by the study 
chairman, Professor Anthony Keech, and the international Management Committee, 
which has representatives from the three participating countries—Australia, New 
Zealand and Finland—and the sponsor, the French pharmaceutical company, Fournier 
Pharma.
The coordinator of the trial at the CTC is  Dr Sarah Blakesmith; Karen Pinto is 
monitoring coordinator. The FIELD New Zealand project oﬃ  ce is led by Dr Caroline 
Lintott from Christchurch, and Anne Salo coordinates the activity across Finland from 
Helsinki. 
Signiﬁ cant absolute beneﬁ ts and harms per 1000 persons treated over 5 years 
in the FIELD study (all P<0.05)
Methodological features 
of the FIELD trial
Patients were only considered if 
the patients’ treating doctors were 
uncertain about the value of lipid-
lowering for the patient and felt 
that there was no deﬁ nite indication 
for such treatment. No patient was 
on lipid-lowering therapy at study 
entry. In this way, the trial was based 
on uncertainty about treatment, or 
equipoise.
When the trial was being planned, 
the statins were showing promise 
as eﬀ ective drugs to reduce the risk 
of cardiovascular disease. Therefore, 
adjusting the eﬀ ects of fenoﬁ brate 
for statin use was planned in the 
protocol. Prespecifying this analysis 
was prescient, as many patients did 
go on to take statins.
Blinded interim statistical reviews 
were planned in the study protocol. 
FIELD patients turned out to be 
healthier than anticipated in the 
original study design. When the 
study was ﬁ rst reviewed, the number 
of participants with prior myocardial 
infarction was less than expected, 
so the sample size was increased. 
On the second review, it became 
apparent that there would be too 
few primary events for the study’s 
power to be maintained, and 
therefore the primary outcome was 
changed from coronary death to 
coronary events. Thus, the protocol 
allowed for diverse contingencies.
The study had a 16-week run-in 
phase before randomisation. For the 
ﬁ rst four weeks, patients followed 
diet recommendations. This was 
followed by a six-week placebo 
period, then a six-week period 
on the study drug. This allowed 
patients time to consider long-
term participation and the doctors 
and researchers to evaluate the 
short-term eﬀ ects of fenoﬁ brate 
treatment.
 NHMRC CLINICAL TRIALS CENTRE: 2004–2005 RESEARCH REPORT 27
PREV
EN
TIN
G
 H
EA
RT D
ISEA
SE
-30
-25
-20
-15
-10
-5
0
5
10
Nonfatal
myocardial
infarction
Cardiovascular
disease
Revascularisation
Hospitalisation
for angina
Amputation
Laser eye
treatment Urinary
albuminuria
Pancreatitis
Pulmonary
embolism
N
um
be
rs
of
ev
en
ts
Report-Shaker[recover].indd   5:27 05/12/2006   06:09:41
28 NHMRC CLINICAL TRIALS CENTRE: 2004–2005 RESEARCH REPORT
With an established team of specialist researchers in clinical trials, the CTC is well 
placed to add value to its main trial ﬁ ndings by conducting substudies or secondary 
analyses that extend the value of trial data. 
Substudies are usually optimally valid when they are designed during the design 
phase of the main trial. The CTC research teams are aware of this, and so the 
feasibility of various additional studies is always taken into consideration when new 
trials are being developed. As well as the planned secondary analyses, other 
substudies may be done as a follow-up to a trial, because the main results are often 
a spur to further exploration of the data.
Types of trial substudy include:
• quality-of-life assessments 
• exploration of treatment mechanisms
• genetic, biochemical and anatomical investigations
• extended follow-up beyond the main trial
• analyses of data from selected patient groups, such as people in an age group
• methodological research work
• health-economic analyses
VIGOUR COLLABORATION
The CTC is currently participating in substudies of the recently completed HERO-2 trial (on page 52), one of 
the large international cardiovascular trials of the VIGOUR collaboration (Virtual Co ordinating Center for Global 
Collaborative Cardiovascular Research), which comprises investigators from academic institutions in over 40 
countries undertaking clinical trials of treatment for acute cardiovascular events. 
In VIGOUR:
• organisations are self-suﬃ  cient, yet working collaboratively
• any investigator or any group can take the lead in a clinical trial
• each organisation maintains suﬃ  cient relevant expertise
• groups have compatible systems and accountability to each other for quality production
• common site data and site descriptors are used across the whole collaboration
• all groups use standard operating procedures for data management, monitoring, audit and biostatistics.
Advantages to the CTC are: access to the latest treatments; making a contribution to important scientiﬁ c 
questions; international resources to tackle questions beyond the capacity of Australian investigators alone; and 
opportunities to consider subsidary research questions and to initiate new questions. The CTC is responsible for 
regional data management and statistical analysis for HERO-2. Professor John Simes is a VIGOUR leader.
VIGOUR COLLABORATION
INIS SUBSTUDY
LIPID SUBSTUDY
FIELD SUBSTUDY
QUALITY-OF-LIFE SUBSTUDY
S U B S T U D I E S  A D D  VA L U E 
T O  C L I N I C A L  T R I A L S
5
SUBSTUDIES ADD VALUE TO CLINICAL TRIALS
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INIS: preventing the damaging eﬀ ects of neonatal infection
Serious infection in a newborn often places the baby at risk of death or permanent 
disability. The International Neonatal Immunotherapy Study (INIS) is a major 
international, double-blind, placebo-controlled randomised trial testing the eﬀ ects of 
immunoglobulin for newborn babies with serious infection.
Newborn infants, particularly those born early, are deﬁ cient in immunoglobulin (IgG) 
and so are at risk of infection. Each year over 2500 babies in Australia and New Zealand 
develop serious infection: about 250 die and another 375 survive with lifelong disability. 
Polyclonal intravenous immunoglobulin (IVIG) may help to reduce death and brain 
inﬂ ammation resulting from infection. 
The trial now has 24 centres actively participating. Of the babies in the trial, 168 have 
reached the two-year mark (95% of these have already been followed up) and 496 have 
reached one year.
Substudies at the CTC
The CTC is the coordinating centre for Australia and New Zealand and is making 
particular contributions to the trial by conducting substudy research.
1. Two substudies on methods to improve recruitment and consent in randomised 
controlled trials in neonatology are in progress (see box opposite).
2. The economic implications of the trial will be assessed by an economic evaluation. 
The costs considered include the study drug (IVIG), hospitalisations, specialist care and 
long-term care of children with a disability, and a sensitivity analysis which uses a range 
of variation to allow for diﬀ erent suppositions. For both treatment and control groups, 
the life years gained and the quality-adjusted life years gained per child after the age of 
two  will be calculated and the diﬀ erence between the randomised groups evaluated. 
Lorraine O’Regan and 
Priya Duggal-Beri (trial coordinator)
 INIS trial
William Tarnow-Mordi is 
principal investigator of INIS. 
He is Professor of Neonatal 
Medicine at the University of 
Sydney, and based at Westmead 
Hospital. He works at the CTC 
on development of neonatal 
clinical trials one day a week. 
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Using INIS to improve 
recruitment in neonatal 
trials: two substudies
After the ﬁ rst years of the INIS 
trial, recruitment began to drop 
below target, leading to a need 
for strategies to increase the 
numbers. The use of educational 
newsletters and DVD videos 
in obtaining consent in large 
randomised trials has not been 
tested in other large trials. The 
coordinating group at the CTC is 
testing these two interventions 
for their value in improving 
recruitment.
These INIS substudies randomly 
allocated sites to either arm or 
to both arms to receive:
• a personalised letter to 
each staﬀ  member with the 
regular monthly newsletter 
and educational supplement 
describing a new topic each 
month (duration: 
six months) 
• a DVD video showing typical 
case scenarios of appropriate 
methods of obtaining 
consent from parents, 
with an actor playing the 
parent, and a supplementary 
booklet.
The eﬀ ect on recruitment will 
be measured by any changes 
in recruitment rates, the 
perceptions of local research 
staﬀ  and the types of babies 
enrolled.
If the study shows that these 
materials are eﬀ ective, tools 
like these may be used in other 
clinical studies and may help in 
aspects of medical practice, such 
as communicating with staﬀ  and 
parents and seeking consent for 
procedures and treatments.
If the trial shows a 3% reduction in permanent disability, it is projected that the cost 
savings to Australian health services will be more than the cost of the INIS trial itself.
3. The INIS study is validating the questionnaires used in Australia and New Zealand, 
with the aim of seeing how well the responses from parents and paediatricians correlate. 
In a further validation, 900 of the 1500 babies to be recruited in Australia and New 
Zealand will be assessed with the Bayley Infant Scales of Development II. The Bayley 
assessment is expensive and labour-intensive, and validation against parent and 
paediatrician questionnaires will provide paediatric researchers with information about 
whether there is a need for this assessment in large pragmatic trials (like INIS). So far, 
158 babies of a planned 900 have had a Bayley assessment.
Eligibility criteria:
• a proven or suspected serious infection, and
• a birth weight under 1500 grams, or receiving artiﬁ cial respiratory support by 
endotracheal tube, or having evidence of infection in a normally sterile site, 
and
• antibiotics already prescribed
Study drug: 
Intragam P or saline (placebo) over four to six hours and repeated after 48 hours
Main outcome measures:
• survival without major disability at two years, corrected for gestational age
• death, infection, chronic lung disease before hospital discharge, major 
cerebral abnormality before hospital discharge, death or disability after two 
years, length of hospital stay, and number of hospital admissions
Recruitment target: 5000 internationally, 1500 in Australia and New Zealand
Recruitment to 2005: 2150 internationally, 1010 in Australia and New Zealand
Funding: 
UK Medical Research Council, Sydney University Sesqui grant, Telstra 
Foundation, Ian Potter travel grant, NHMRC, Financial Markets Foundation for 
Children, NZ Health Research Council.
INFECTION TREATED WITH ANTIBIOTICS
IN NEWBORN BABY
DEATH OR DISABILITY AT 2 YEARS OF AGE
Placebo infusionIntravenous
immunoglobulin
5
SUBSTUDIES ADD VALUE TO CLINICAL TRIALS
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Helen Pater
LIPID trial manager
LIPID trial: pravastatin treatment for up to 11 years
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial was 
the CTC’s ﬁ rst large, long-term multicentre trial. It showed that lipid lowering with 
pravastatin prevented recurrent coronary heart disease events in 9014 patients. 
Patients continued to be followed up after the trial ﬁ nished in 1997, and data are still 
being collected over seven years later. Since the end of the trial, about 85% of patients 
have continued on lipid-lowering therapy, the most common being the original 
pravastatin. 
After 1999, funding for clinic visits ceased and patients have since been followed up 
by letter and telephone, in addition to searches of directories, disease registers and 
electoral rolls. The aim of the extended follow-up is to examine the long-term safety 
and cost-eﬀ ectiveness of pravastatin treatment and to assess the eﬀ ects of treatment 
on the risk of outcomes such as total mortality, coronary heart disease mortality, acute 
myocardial infarction, stroke, cancer and other major cardiovascular events.
In 2005, the results of 11 years of follow-up were presented at the Annual Scientiﬁ c 
Sessions of the American Heart Association. Data were missing for only 185 of the 
original cohort of 9014. People who were originally allocated to pravastatin over the 
initial six years of the trial, compared with those allocated to placebo, continued to 
beneﬁ t from the initial pravastatin treatment. As well, there was no evidence of harm 
(such as cancer) from long-term treatment.
Lipid-lowering treatment for people with low cholesterol
About a third of the patients in the LIPID trial had low levels of both high-density 
lipoprotein cholesterol (good cholesterol) and low-density lipoprotein cholesterol (bad 
cholesterol), a subgroup for whom a ﬁ brate or nicotinic acid is often recommended. 
In the light of these recommendations, the LIPID investigators decided to undertake a 
subgroup analysis of the beneﬁ ts of pravastatin for these patients. Treatment reduced 
their risk of coronary events, death and, in particular, stroke. These results were 
published in the European Heart Journal in 2005.
Cost-eﬀ ectiveness in the older patient group
Prevention and treatment of cardiovascular disease are responsible for the highest 
proportion of total health expenditure, by disease group, in Australia, attributable to 
hospital treatment, medication and nursing home care. Hospital costs are higher in 
the elderly, owing to the complexity of their disease and a higher incidence of other 
conditions. Such treatment burden is projected to increase further as the population 
ages. 
A LIPID substudy showed in 2001 that pravastatin treatment was just as eﬀ ective 
for patients aged 65 years and over as for younger patients. For each 1000 patients 
aged 65 to 74 years at at the start of the LIPID study, six years of pravastatin therapy 
prevented 43 deaths, 33 myocardial infarctions, 32 hospitalisations for unstable 
angina, 13 strokes, or 133 major cardiovascular events.
Costly treatment with cholesterol-lowering drugs has often been withheld from elderly 
patients because it used to be thought that cholesterol levels were less of a risk factor 
in this population.  The LIPID investigators recently carried out an economic analysis of 
the use of pravastatin in the younger compared with the older subgroup, which is to be 
published in 2006.
»
Report-Shaker[recover].indd   Sec5:31 05/12/2006   06:09:43
32 NHMRC CLINICAL TRIALS CENTRE: 2004–2005 RESEARCH REPORT
New information from substudies of the FIELD trial
— a study of 9795 patients with diabetes
The FIELD trial investigated the use of fenoﬁ brate lipid-lowering treatment to prevent 
heart disease among patients with diabetes (see page 26). 
Carotid artery measurement substudy
A substudy from the trial was published in 2005. A sample of about 400 patients from 
FIELD had carotid ultrasound to measure the thickness of the intima-media layer of 
the carotid artery wall. Intima-media thickness is a well-described early indicator of 
cardiovascular disease and is known to be higher in people with diabetes.
People with a longer duration of diabetes had a thicker intima-media layer. The main 
ﬁ nding of interest in this substudy was that the thickness was related to the level of 
albumin in the urine, even for levels in the normal range.
Ongoing substudies
Now that the main results of the FIELD trial have been published, the data are being 
analysed for other substudies that were planned before the trial began: on clinical aspects, 
such as vision changes (1200 patients) and quality of life (1500 patients), and laboratory-
measured aspects, such as the relationship between fenoﬁ brate lipid-lowering treatment 
and the distribution of lipid particle sizes in the blood (2000 patients).
Nutrition
Diet was an important consideration in the LIPID study. Partipants received dietary advice before the trial began and at 
intervals during the trial. A sample of 1077 people took part in a survey of their eating habits when the trial began, and 
most of these also took part in follow-up surveys as the trial progressed. 
In a substudy published in the American Journal of Clinical Nutrition in 2005, the higher coronary heart disease mortality 
over the period of the trial in patients from New Zealand was reported to be related to the amounts and types of dietary 
fats reported in the initial survey. 
Genetic and biochemical studies
Blood samples collected over the ﬁ rst six years of the study are now being analysed in relation to various risk factors and 
biomarkers for cardiovascular disease to investigate the importance of new potential prognostic markers of cardiovascular 
disease.
A case–control substudy found that brain natriuretic peptide (BNP) levels predicted the risk of recurrent cardiovascular 
events independently of other factors such as the LIPID risk score (see page 51), treatment with pravastatin and levels 
of other biomarkers. In another case–control study, the biomarker TIMP-1 (tissue inhibitor of metalloproteinases), was 
found to be associated with higher cardiovascular risk; this was interpreted as a possible protective mechanism against 
metalloproteinases. Leptin, a hormone produced by fat cells, may be a link between obesity and cardiovascular disease. 
Leptin levels in blood samples from men in the LIPID study were investigated in another substudy, which showed that 
leptin levels predict recurrence of cardiovascular disease. These studies were presented at international meetings in 2005.
The mechanism of action of pravastatin, and its relationship with coenzyme Q10, was explored in a prospectively planned 
study of blood plasma samples from patients who subsequently died from a cardiovascular cause or had a myocardial 
infarction or stroke, compared with control patients. This substudy will be published early in 2006.
Claudia Anderson
Coordinator of the FIELD 
ophthalmology substudy
SUBSTUDIES ADD VALUE TO CLINICAL TRIALS
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Martin Stockler
Co-director of cancer trials
Quality-of-life substudies add value to trials
A guiding principle at the CTC is that direct measures of beneﬁ t, harm and cost are 
incorporated into trials during their design, so that data collection is optimal. An 
important aspect of our research program is to improve the methods of assessment of 
quality and cost data and to integrate measures of quality of life, utility, preference and 
resource use.
Quality-of-life assessment includes utility-based measures for heart disease patients 
(UBQ-H) and cancer patients (UBQ-C), developed at the CTC. Quality-of-life, utility and 
survival are combined by using quality-adjusted survival analysis, also developed at the 
CTC. Recent studies on quality of life in cancer have been done by Vlatka Duric, Anna 
Nowak, John Simes, Martin Stockler and others.
Quality of life in the phase II study of octreotide in advanced 
hepatocellular carcinoma 
This 63-patient study has been completed and a manuscript submitted for publication 
by the study investigators. The analysis has concentrated on describing the baseline 
quality of life of these patients and validation of both the previously reported FACT-
Hep and a novel tool, the Patient Disease and Treatment Assessment Form, which was 
developed at the CTC. 
Assessing quality of life in routine clinical practice
This study assessed the use of the Patient Disease and Treatment Assessment Form 
by outpatients with cancer. Patients completed the forms while waiting to see the 
oncologist. The items cover physical and emotional symptoms of cancer and wellbeing. 
The aim is to use the form in practice to provide information to clinicians and to 
improve care.
Analysis and validation of baseline quality-of-life data 
from the ANZ 0001 trial
ANZ 0001 is an ongoing multicentre study of capecitabine versus cyclophosphamide–
methotrexate–5-ﬂ uorouracil (CMF) chemotherapy as ﬁ rst-line chemotherapy for 
advanced breast cancer. Quality of life and  treatment acceptability are key outcome 
measures. The study uses the Chemotherapy Acceptability Questionnaire, a new 
instrument developed by the CTC, as well as other validated tools. A substudy describing 
quality of life in the ﬁ rst 150 women randomised to the trial and information on the 
validity of the questionnaires was presented at the annual meeting of the American 
Society of Clinical Oncology in 2004. 
Quality of life in cervix cancer
This multinational collaborative project of the European Organisation for Research and 
Treatment of Cancer (EORTC) to develop a quality-of-life module for cervix cancer trials 
involves the Australia New Zealand Gynaecological Oncology Group (ANZGOG) and the 
CTC, and is being led in Australia by Vlatka Duric.
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An important purpose of the CTC is to work toward improving the eﬃ  ciency and 
utility of clinical trials, throughout Australia and elsewhere. One way of doing this is 
by methodological research, particularly in biostatistics. Clinical trials raise 
questions for methodological research, and then the results of methodological 
research can be applied to the design, conduct and analysis of a wide  range of 
clinical trials. The research therefore bears upon practical and real-life clinical 
problems. 
Better biostatistical methods are continually being sought and tested. Knowledge 
gained from these methodological projects is spread beyond the CTC through major 
educational projects, such as the program of the Biostatistical Collaboration of 
Australia, publications, and the CTC’s many alliances and partnerships.
Trials are conducted rigorously in accordance with the appropriate regulatory 
requirements. The CTC has established an organisational structure with assigned 
responsibilities and authorities to manage and assess the quality of systems and 
services. Trial operations are continually assessed, audited and improved.
Biostatistics projects
A new modiﬁ cation to dynamic-balancing randomisation
Random allocation of participants to treatment groups is fundamental to clinical trial 
design. In simple randomisation, participants are allocated from random number 
sequences. Better balance of the characteristics of participants across the treatment 
groups can be achieved by more sophisticated methods of random allocation. 
Randomisation methods that balance treatment allocation according to known 
prognostic factors are well established and are used in practice. However, they continue 
to be improved.
Biostatisticians from the CTC have 
recently completed and published a 
modiﬁ cation of a method previously 
developed at the CTC, dynamic-balancing 
randomisation. Participants are allocated 
to treatment groups after a check of 
previous allocations according to a 
hierarchy of strata; that is, imbalances 
across treatment groups in important 
characteristics (deﬁ ned before the trial) 
can be corrected ﬁ rst. The method was 
compared with other randomisation 
methods by simulation in two trials.
BIOSTATISTICS PROJECTS
TRIALS ON TRIAL
AUDIT AND QUALITY ASSURANCE
I M P R OV I N G  T H E  CO N D U C T  O F 
C L I N I C A L  T R I A L S
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Some of the CTC’s biostatisticians: 
Avinesh Pillai, Rachel O’Connell, 
Peta Forder, Adrienne Kirby, 
Stephane Heritier, Tatiana Sourjina 
and Chris Brown
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Val Gebski
Head of Biostatistics
A new approach to interim analyses
Current research projects are focusing on statistically valid and eﬃ  cient ways to use 
preliminary outcome data from patients when ﬁ nal data are not yet available. In some 
trials the outcomes of patients are reported by sites but it takes time for these outcomes 
to be properly conﬁ rmed by the adjudication of a central committee. This research will 
allow more eﬃ  cent, and earlier, identiﬁ cation of treatment diﬀ erences. The statistical 
method uses the strength of association between the preliminary and ﬁ nal outcome 
status to obtain a valid result from preliminary data. 
Competing risks
The multiple outcomes of patients in clinical trials complicate the statistical analysis of 
the results. In a cancer clinical trial, for example, an investigator may wish to estimate 
the eﬃ  cacy of treatments by comparing patients’ survival in the two arms of the trial. 
However, the patients may also die from other causes. Estimating patients’ survival 
requires statistical models that measure the risks of diﬀ erent events; when the risks of 
diﬀ erent events are aﬀ ected by each other (competing risks), the models must account 
for this. Biostatisticians are analysing these risks in simulation studies in order to arrive 
at the best models of survival in these situations.
Surrogate outcomes
A surrogate outcome is an intermediate measure that is related to the main outcome 
of a trial. A research interest of the CTC is the degree to which a surrogate is associated 
with the main outcome, and how well this can be measured. Often, because of costs 
or other factors, the potential surrogate outcome will only be measured in a substudy 
of the main trial. In this situation, the substudy patients provide information about 
the links between the true and surrogate outcomes and the treatment, and such 
correlations can be used to allow available data for patients not in the substudy to be 
included in the analysis. This leads to more precise estimates of the treatment eﬀ ect. 
This was the subject of an article recently published in Statistics in Medicine.
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IMPROVING PATIENT COMPLIANCE IN LONG-TERM TRIALS
A large clinical trial can be an opportunity for research projects exploring ways of improving the conduct of future trials. 
Wendy Hague completed a PhD in 2004 on strategies for improving patient compliance with treatments in long-term trials. 
The topic issued from earlier work on recruitment strategies in the LIPID trial.  The objective was to determine whether 
site management practices and staﬀ  characteristics, in addition to patient attitudes and behaviours, were associated with 
subsequent discontinuation of study medication.
The information obtained was used in the design of a prospective substudy for the CTC’s large trial, FIELD. A questionnaire 
was developed, which was completed by patients when they were recruited into FIELD; the analysis, which will be conducted 
after the close of the FIELD study, will show, in a prospective study, the characteristics associated with patients changing their 
medication.
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Graphical methods for assessing factorial designs
A two-way factorial design can be a way of answering two questions in a single 
clinical trial. The power of the trial to study each of two treatments can be similar to 
that of a simple two-arm trial with the same sample size. However, if the treatments 
interact (reinforce or antagonise each other), the assessment of power becomes more 
complicated.
Biostatisticians at the CTC have developed a method for examining the loss of power 
due to the presence of an interaction in such a trial. The power of a two-way factorial 
design over a range of interaction values can be compared with that of a three-arm 
study to show which will be more economical in terms of sample size. The study was 
published in Clinical Trials.
Analysing variability in meta-analysis
Evidence from randomised trials is the gold standard for comparisons of medical 
interventions, but there is often other evidence from observational and other studies 
that could contribute information to such comparisons. However, these studies 
can be confounded by other factors, leading to bias. Meta-analytic approaches that 
combine evidence across a range of studies, both randomised and observational, make 
it possible to test for the presence of speciﬁ c eﬀ ects and therefore make use of these 
nonrandomised studies.
The heterogeneity of treatment eﬀ ects associated with diﬀ erent classes of design 
was assessed in a methodological study that provided models for analysing reported 
summary statistics and for calculating weightings of evidence contributed by the 
diﬀ erent classes of study in meta-analysis. Variation in results among case–control, 
prospective, and other study types was examined and compared with the eﬀ ects found 
in two large clinical trials. The result from the ﬁ nal model corresponded to the pooled 
eﬀ ect and reduced the uncertainty of the risk estimate from the ﬁ ndings of the trials 
alone.
Longitudinal nonparametric methods
Recent research on nonparametric methods is improving the validity of quality-of-life 
and other analyses in which the distributions of data are not normal, such as repeated 
measures of ordinal outcomes and multistate responses. The CTC’s biostatisticians are 
improving the methods of analysis of these data sets. The methods are being applied to 
the design of new trials to improve eﬃ  ciency and ﬁ nd the right sample size, therefore 
minimising costs.
Relative eﬃ  ciency of parametric and bootstrap estimates of costs
Large randomised trials commonly provide quality-of-life and cost data in addition 
to data for answering the trial’s main question. These data are collected for important 
substudies to establish the beneﬁ ts and costs associated with a new treatment. 
However, the  data are not normally distributed, and established methods of analysis 
are not ideal. In a recent study, the biostatisticians have been using a new method of 
analysis by transforming the data and using parametric methods. The method appears 
to be more accurate and eﬃ  cient than previous approaches, and is likely to be useful in 
cost-eﬀ ectiveness analyses in future trials.
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Two designs for 
comparing treatments 
in clinical trials
Two-way factorial trial design
Placebo Drug 1
Placebo Group 1 Group 2
Drug 2 Group 3 Group 4
Groups 2 and 4 are the 
intervention group for drug 
1, and groups 3 and 4 are the 
intervention group for drug 2.
Three-arm trial design
Placebo Group 1
Drug 1 Group 2
Drug 2 Group 3
This design has no Group 4, 
that is, no patients taking both 
drugs.
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Trials on trial: a CTC initiative for better conduct and 
reporting of clinical trials
A recent series of articles in the Medical Journal of Australia, designed to improve the 
conduct and reporting of clinical trials in Australia and internationally, has been a way in 
which the CTC has met its commitment to better trials through educational activity.
Much of the rapidly increasing trials research over the past half century (see graph) has 
been poorly  or inadequately reported. The international standard dealing with this is 
the CONSORT (Consolidated Standards of Reporting Trials) statement, which is in the 
form of a checklist of essentials for running a trial and writing the paper for a scientiﬁ c 
journal. The statement was revised and extended between 1996 and 2001. The MJA 
series clariﬁ es and illustrates the 22 descriptors in the CONSORT list.
The articles were originally written in order to demystify the the technical language of 
evidence-based medicine for clinicians. However, the series has been useful for a wide 
range of readers—including anyone wanting to know from reading a journal article 
whether all the information has been properly reported and the results are valid.
The ﬁ rst article described the elements of a good study, and subsequent articles have 
dealt with issues such as the design of a trial, including acceptable randomisation 
and blinding methods, how to choose an intervention and its outcome measures, 
and calculating sample size; the conduct of a study, including recruitment and data 
collection; reporting results, including adverse events and how to consider subgroups; 
and how to interpret the evidence, taking into account possible bias or imprecision.
The articles also emphasise biostatistical analysis of trials data, reﬂ ecting the expertise 
of the CTC in this area. Authors of the articles in this series have been various clinical 
trials practitioners, from the CTC and elsewhere, whose expert knowledge has been 
integrated into the theme crafted by Tony Keech and Val Gebski, the co-authors on all.
Reports of randomised controlled trials compared 
with total publications 
(Source: PubMed)
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Quality assurance and audit
Generating reliable clinical data is essential for every clinical study, and the CTC’s quality 
assurance program has been developed to ensure this. Combining eﬀ ective operating 
procedures with education and training for all staﬀ  has been a successful approach 
to achieving data integrity, compliance with regulatory requirements and optimal 
outcomes for the CTC’s clinical projects.
As a minimum, all staﬀ  involved with a clinical study have participated in a 
comprehensive course in Good Clinical Practice (GCP) principles in the Australian 
regulatory context. A set of CTC policies, standard operating procedures and work 
instructions form the backbone of the quality assurance program. This program is 
regularly reviewed. For example, in the past two years, the document-control system for 
standard operating procedures and archiving were upgraded and a quality-assurance 
web site was developed to increase access of staﬀ  to regulations, CTC policies, standard 
operating procedures, work instructions and templates for use in project work.
Four external audits have been conducted during the past two years. A trial of a 
new treatment for colorectal cancer, NCIC CO 17, was externally audited by the 
pharmaceutical company, Bristol-Myers Squibb in the USA, and the C06 and C07 
colorectal carcinoma trials were audited by the international lead coordinating 
cooperative group, the US National Surgical Breast and Bowel Project (NSABP). 
In addition, procedures for randomisation and statistical analysis, which the CTC 
undertakes for the Australian New Zealand Breast Cancer Trials Group (ANZ BCTG), 
were reviewed by two expert consultants in biostatistics and data management. The 
observations were favourable and future trials with these groups are forthcoming.
PROMOTING HIGH STANDARDS THROUGH EDUCATION 
AND TRAINING
All new clinical staﬀ  at the CTC are trained in Good Clinical Practice and 
speciﬁ c standard operating procedures. During 2005, the knowledge and 
skills for preparing and conducting an audit were presented at workshops for 
the Cancer Council, the Australasian Gastro-Intestinal Trials Group and the 
Australasian Health and Research Data Managers’ Association. 
Laurie Snaith 
Head, quality assurance and audit
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Combining the evidence from multiple clinical trials in a systematic review is a 
powerful tool for answering important clinical questions when a single deﬁ nitive 
large-scale trial has not been conducted. Systematic reviews combine the results of 
all relevant high-quality studies that ask the same clinical question. An important 
role of the CTC is extracting the best evidence from the available trials.
Even more powerful is combining trials before they have started, so that the 
question in the review uses prospective data. The CTC is a leader in prospective 
meta-analysis projects and in methods for their conduct and analysis. Several of 
the CTC’s trials have been a part of international prospective meta-analysis 
collaborations.
Systematic reviews by the Cochrane Collaboration
The Cochrane Collaboration is the largest organisation in the world engaged in the 
production and maintenance of systematic reviews of health care interventions. 
The reviews are available through the Cochrane Library collection (which is free to 
Australians) via the internet.
COCHRANE COLLABORATION
PROSPECTIVE META-ANALYSIS
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COCHRANE REVIEW PROCESS
CO M B I N I N G  T R I A L  E V I D E N C E
INTERNAL AND EXTERNAL OF PROTOCOLPEER REVIEW
PROTOCOL FINALISED
INTERNAL AND EXTERNAL OF REVIEWPEER REVIEW
SYSTEMATIC REVIEW FINALISED
PUBLICATION IN THE COCHRANE LIBRARY NEW TRIALS PUBLISHED AND/OR RECEIVED FROM USERSCOMMENTS
REVIEW AUTHORS PREPARE FOR SYSTEMATIC REVIEWPROTOCOL
SEARCH IS CONDUCTED AND RELEVANT TRIALS IDENTIFIED
SYSTEMATIC REVIEW COMPLETED
REVIEW IS UPDATED
CLINICAL QUESTION
DEFINED BY REVIEW AUTHORS AND EDITORIAL BASE
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The Cochrane Breast Cancer Group is a review group of the Cochrane Collaboration. Its 
activities are coordinated by a team of editors based at  the CTC. The group compiles 
evidence relating to the management of women with breast cancer. Through the 
coordination of systematic reviews, staﬀ  at the CTC are also actively engaged in 
developing protocols for new reviews and training new authors.
The Cochrane Breast Cancer Group continues to receive support and funding from the 
Commonwealth Department of Health and Ageing via a program to support Australian-
based Cochrane Collaboration activities. 
Recent reviews by CTC members of the 
Cochrane Breast Cancer Group
Single-agent therapy compared with combination chemotherapy for 
metastatic breast cancer
One way to investigate the eﬀ ect of more-intensive compared with less-intensive 
chemotherapy is to compare regimens containing a single drug with regimens 
containing more than one drug (possibly more active but more toxic). Data from 
trials focusing on such questions were investigated in this systematic review.
It was found that adding chemotherapy agents to the same single-agent cytotoxic 
generally resulted in a more intense chemotherapy regimen, with both better tumour 
response and worse toxicity. These more intense therapies were usually associated with 
better progression-free and overall survival, especially when the single agents were the 
more traditional drugs. The ﬁ ndings are not necessarily applicable to some of the more 
modern single agents, such as the taxanes and capecitabine. 
Antitumour-antibiotic-containing regimens for metastatic 
breast cancer
Several large randomised trials have supported the use of the antitumour antibiotics 
over standard CMF (cyclophosphamide, 5-ﬂ uorouracil, methotrexate) regimens, but the 
evidence for survival beneﬁ t has not been conclusive. 
This review found that chemotherapy that included antitumour antibiotics was more 
likely to result in tumour response but did not improve survival of women with advanced 
breast cancer when compared with chemotherapy that did not contain these types of 
drugs. Doxorubicin and related drugs might decrease the cancer’s progression but also 
increase adverse eﬀ ects, including heart failure.
Taxane-containing regimens for metastatic breast cancer
Taxanes are among the most active chemotherapy agents for advanced breast cancer. 
In a systematic review, taxane-containing chemotherapy regimens were compared with 
regimens not containing a taxane for women with metastatic breast cancer. 
Taxanes were reported to be more eﬀ ective than some, but not all, regimens with which 
they were compared, and of the two major taxanes, docetaxel may be more active than 
paclitaxel.
Platinum-containing regimens for metastatic breast cancer
This review looked at trials of treatment that included platinum, alone or in combination 
with other chemotherapy drugs, for advanced breast cancer.
The ﬁ ndings of of signiﬁ cant excess toxicity, apparent lack of beneﬁ ts for overall 
progression or survival, and the availability of less toxic and eﬃ  cacious agents, spoke 
against the use of platinums in routine clinical practice, at least as a ﬁ rst option.  
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Not all the CTC’s 
Cochrane reviews are in 
breast cancer …
Tamoxifen for 
hepatocellular carcinoma
Tamoxifen, which acts on 
oestrogen receptors, is a 
commonly used treatment for 
preventing recurrence of breast 
cancer. Cells of hepatocellular 
carcinoma (liver cancer) also 
have oestrogen receptors, an 
observation which led to trials 
of tamoxifen for patients with 
this disease. They have had 
conﬂ icting results. A systematic 
review of ten trials showed that 
tamoxifen had no signiﬁ cant 
eﬀ ect on survival or tumour size 
and did not improve quality of 
life. The results of this review, 
prepared for the Cochrane 
Library, were also published in 
Cancer.
SUPPORT AND 
INFORMATION PACK 
EVALUATED
The CTC staﬀ  working for the 
Cochrane Breast Cancer Group 
evaluated the new Support and 
Information Pack, developed by the 
Cancer Council NSW for patients 
with a new diagnosis of cancer.
The evaluation aimed to determine 
the perceived usefulness of the pack 
to patients, their carers and families 
and health professionals, and also 
to make recommendations to 
improve further evaluation of the 
information pack.
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Drugs used in chemotherapy for breast cancer
Taxanes
The ﬁ rst taxane, paclitaxel, was obtained from the Paciﬁ c yew tree, Taxus 
brevifolia. Taxanes can now be derived from other species of yew. Taxanes block 
the normal disintegration of intracellular spindles, preventing the separation of 
chromosomes, and therefore stopping cell division and multiplication.
Antibiotics
Doxorubicin and mitomycin are derived from the fungus, Streptomyces 
peucetius. Antitumour antibiotics act by binding to DNA, preventing 
transcription and therefore nucleic acid synthesis and also by inhibiting 
enzyme activity and causing DNA to break.
Alkylating agents
Cyclophosphamide, one of the early anticancer drugs, is the most common 
alkylating agent used for breast cancer. It is metabolised in the cell to form an 
active agent, which attacks DNA, preventing it from uncoiling, and so stops 
cell function. More recent alkylating agents are the platinums, cisplatin and 
carboplatin, whose mechanisms of action are not so clearly deﬁ ned.
Vinca alkaloids
Vinblastine and vincristine are alkaloids found in the Madagascar periwinkle, 
Catharanthus roseus. They act by binding to tubulin, preventing the cell from 
forming spindles and dividing.
Antimetabolites
Antimetabolites, ﬁ rst used in 1948, mimic natural intracellular compounds 
and block biochemical pathways. The antimetabolite, 5-ﬂ uorouracil, prevents 
DNA synthesis. 
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In November 2004, the Cochrane 
Breast Cancer Group conducted a 
workshop, “How to read and do 
a Cochrane systematic review”, 
attended by people representing 
a range of disciplines, including 
clinicians and consumers.
In May 2005, the group conducted a 
protocol-development workshop.
In October 2005, the group, in 
conjunction with the Breast Cancer 
Action Group, conducted a forum, 
“Decision making in breast cancer: 
making the best of the evidence”, in 
Melbourne in association with the 
annual Cochrane Colloquium. 
The audience included women 
with breast cancer and associated 
clinical professionals. Among the 
topics presented by the seven 
internationally and nationally known 
speakers were results from the latest 
trials of breast cancer treatment and 
interpretation of the evidence they 
provide.
Systematic reviews group: 
Davina Ghersi, Sally Lord, Nicole Holcroft, Lisa Askie, Jenny Chow, Silke Walleser, Sharon Parker, Suzanne Dyer
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Prospective meta-analysis of data from clinical trials
In a meta-analysis, the results of more than one independent clinical trial are integrated. 
In a prospective meta-analysis, the hypotheses and analyses for the combined data are 
planned before the constitutuent trials have ﬁ nished. The investigators agree to pool 
their future data. Ideally, these decisions are made during the conception and design 
stage of the trials so that the the criteria for deﬁ ning endpoints and so on can be similar 
where possible. 
Prospective meta-analysis analysis is a powerful and scientiﬁ cally rigorous approach to 
combining trial evidence, with the strengths of a single large trial. The trials, treatments, 
subgroups, outcomes and analysis plans are all prespeciﬁ ed before the results of the 
constitutuent trials are known
The CTC is a member of several collaborations and is a leader in prospective meta-
analysis methodology.
Cholesterol lowering with pravastatin: 
the Prospective Pravastatin Pooling project
The investigators from the LIPID, CARE, and WOSCOPS trials formed the PPP in 1992 
to combine data from the three large trials of lipid-lowering with pravastatin. The 
objective was to use the pooled data to study the eﬃ  cacy of pravastatin in reducing less 
common events, such as stroke, and in subgroups whose numbers were too small in the 
individual trials. The protocol was published in 1995. John Simes and Tony Keech are 
members of the international steering committee.
Since the end of the last of these trials, LIPID, in 1998, several meta-analyses have 
been completed. The group recently published studies of the eﬀ ects of pravastatin for 
patients with chronic kidney disease. It was shown that the drug was beneﬁ cial for these 
patients (especially those at higher risk) as well as reducing cardiovascular risk, and may 
also modestly reduce the rate of kidney function loss.
Prospective meta-analysis in colorectal cancer
In patients with advanced cancer of the colon but with no symptoms, chemotherapy 
may be given immediately on diagnosis or may be withheld until symptoms develop. 
Chemotherapy (with its side-eﬀ ects) for a patient who initially feels well needs to 
be justiﬁ ed by evidence that it has a beneﬁ t. The timing of chemotherapy has been 
the subject of debate.  Inconclusive results from clinical trials and a range of opinions 
among medical oncologists who treat colorectal cancer led to two trials of immediate 
chemotherapy compared with deferred therapy, in Australia and in Canada.
The investigators from both trials designed a meta-analysis of the combined results 
before the trials began. This was wise planning because the numbers of patients 
eventually recruited were too low in the individual trials, but the meta-analysis went 
ahead. Results were published recently in the British Journal of Cancer. 
7
COMBINING TRIAL EVIDENCE: PROSPECTIVE META-ANALYSIS
GRANT FOR 
SYSTEMATIC REVIEW  OF 
INTERVENTIONS FOR 
LOCALLY ADVANCED 
BREAST CANCER
In 2005, the CTC received a grant 
from the Cure Cancer Australia 
Foundation for a systematic review 
of interventions for locally advanced 
breast cancer.
The systematic review process will 
lead to identifying current trials 
which are yet to answer questions 
about treatment and areas where 
properly designed trials should be 
undertaken. The review is likely to 
ﬁ nd current gaps in evidence-based 
information and to contribute to 
improved clinical practice guidelines.
The objective is better outcomes 
for women who have multimodal 
treatments for breast cancer, such 
as several chemotherapy drugs or 
chemotherapy with radiotherapy.
The principal investigators are 
Nicholas Wilcken and Davina Ghersi.
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CTTC TRIALS
Study Date of 
results
Number of 
participants
Target population
4S 1994 4 444 Prior heart disease
WOSCOPS 1995 6 595 Men with high cholesterol, no heart disease
CARE 1996 4 159 Prior heart disease
Post-CABG 1997 1 351 Prior coronary artery bypass grafting
AFCAPS/ TexCAPS 1998 6 605 No heart disease
LIPID 1998 9 014 Prior heart disease
GISSI-P 2000 4 271 Prior heart disease
LIPS 2002 1 677 Prior heart disease
HPS 2002 20 536 High risk of heart disease
PROSPER 2002 5 804 Elderly
ALLHAT 2002 10 355 Hypertensive
ASCOT 2003 10 305 Hypertensive + 3 risk factors
ALERT 2003 2 102 Renal transplant
CARDS 2004 2 838 Diabetes + 1 risk factor
Tatiana Sourjina, statistician for the CTTC
Eﬃ  cacy and safety of long-
term cholesterol lowering: 
Cholesterol Treatment Trialists’ 
Collaboration (CTTC)
In 1990, the investigators from several 
cholesterol-lowering trials came together 
and decided to pool the data from trials 
of lipid-modifying treatments in future 
analyses. It had been well known that 
lower cholesterol levels are associated 
with lower risk of coronary heart disease. 
Several large trials of statin cholesterol-
lowering drugs in the 1990s showed that 
lowering cholesterol (particularly LDL 
cholesterol) was beneﬁ cial in reducing 
the risk of coronary events in general for a wide range of people. However, the individual 
trials were not large enough to show the eﬀ ects of statins on the risk of death from 
coronary heart disease or on other speciﬁ c outcomes (such as stroke), particularly in 
subgroups of participants. 
The main analyses were to be of the eﬀ ects on death from any cause, death from 
coronary heart disease, and death from other causes. Secondary analyses were eﬀ ects 
on stroke, cancer and vascular procedures. Events in subgroups (such as people with 
diabetes or hypertension, men and women) were also to be analysed. 
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The ﬁ rst of these analyses was reported in The Lancet in 2005. Data from 90 056 
participants were analysed. The study conﬁ rmed the beneﬁ t of using statins to prevent 
coronary heart disease events and showed that the eﬀ ects were related to the reduction 
in LDL cholesterol achieved.
Tony Keech is joint coordinator of the collaboration and was on the writing committee 
of this important publication, with Christine Pollicino, Adrienne Kirby, Tatiana Sourjina, 
and John Simes.
Primary coronary angioplasty vs thrombolysis (PCAT) 
collaboration
The PCAT collaboration undertakes meta-analysis of clinical trials investigating 
the relative beneﬁ ts of treatments to restore coronary blood ﬂ ow after myocardial 
infarction. In a recent meta-analysis the group reanalysed individual-patient data from 
25 trials to determine the role of delays in starting treatment in comparisons of blood-
modifying drug treatments (ﬁ brinolysis) and vessel-opening procedures (percutaneous 
coronary angioplasty, which involves extra delay). Time to treatment was an important 
determinant of the outcome, but primary percutaneous coronary angioplasty was 
associated with lower mortality at 30 days, regardless of delays.
John Simes is co-coordinator of the collaboration.
Combining new trials of deep-vein thrombosis: 
the international ASPIRE–WARFASA collaboration
The investigators of ASPIRE (Aspirin to prevent recurrent venous thromboembolism) 
(see page 16) are collaborating with the investigators of the WARFASA study (initiated 
in Italy) in the prospectively designed meta-analysis, INSPIRE. The two trials have similar 
study designs and the two management committees have harmonised the protocols to 
allow a prospective meta-analysis to be done. 
In INSPIRE, the combined analysis uses individual patient data from both trials. With 
a planned combined enrolment of 3000 patients, the meta-analysis will have more 
than 90% power to detect a 30% risk reduction in recurrent thrombosis with aspirin 
compared with placebo. Patients will be followed up for an average of three years. 
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Finally, an Australian register of clinical trials
The Australian Clinical Trials Registry (ACTR) was established at the CTC in 2005, with 
funding of $1.5 million over ﬁ ve years from the National Health and Medical Research 
Council (NHMRC). The registry is an on-line, comprehensive, prospective, national 
register of all clinical trials being conducted in Australia.
The need for a national clinical trials register had been recognised for many years, but 
this was brought to a head by the announcement from the International Committee of 
Medical Journal Editors (ICMJE) in September 2004 that articles reporting trials would 
be published only if the trial had been publicly registered before the ﬁ rst patient was 
enrolled. Their deadline for registration of new trials was 1 July 2005 and for ongoing 
trials was 13 September 2005. Therefore the ACTR was established within a few months 
during 2005. The ACTR team is working with the NHMRC and the Therapeutic Goods 
Administration to further reﬁ ne and develop the registry. 
The register includes trials from the full spectrum of therapeutic areas—
pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment 
and rehabilitation strategies and complementary therapies. It covers all clinical trials 
involving Australian researchers or Australian participants. The registry will prove to 
patients and health practitioners that the treatment options they choose are based on 
the most up-to-date and comprehensive information available.
The Australian Clinical Trials Registry has been reviewed by the International Committee 
of Medical Journal Editors who have declared that the registry meets their requirements. 
As part of a program to coordinate registration of trials worldwide, the World Health 
Organization has recently set up the WHO International Clinical Trials Registry Platform 
(ICTRP), which is linking the national registries, including the Australian registry. 
The executive group for the 
ACTR is Lisa Askie, Davina 
Ghersi and John Simes. Davina 
Ghersi is also a member of the 
scientiﬁ c advisory group of the 
WHO International Clinical Trials 
Registry Platform and chair of 
the ICTRP Member Registers 
Working Group.  
B R I N G I N G  A N  E V I D E N C E  B A S E  T O 
D EC I S I O N  M A K I N G  A N D  P O L I C Y
WWW.ACTR.ORG.AU
Emma Smith
ACTR project oﬃ  cer
AUSTRALIAN CLINICAL TRIALS REGISTRY
ASSESSMENT OF NEW TECHNOLOGIES, 
TESTS AND PROCEDURES
HEALTH ECONOMICS
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 BENEFITS OF THE AUSTRALIAN CLINICAL TRIALS REGISTRY
Patients and health professionals have access to a searchable, accessible, and comprehensive 
register. Patients and health professionals have greater assurance that all clinical trials results 
are reported, including those with adverse ﬁ ndings.
The registry will increase the eﬃ  cacy of the current clinical trial eﬀ ort through: 
• greater eﬃ  ciency because gaps in research can be identiﬁ ed and duplication of research 
eﬀ ort will be less
• the potential for recruiting more trial participants (especially for rare or life-threatening 
conditions), because potential patients and their doctors will be aware of the trials 
available
• more incentive for publishing trial results, even when the results are unfavourable
• providing a reliable and unbiased source of information for systematic reviews, 
prospective meta-analyses and evidence-based guidelines.
MINIMAL REGISTRATION 
DATA SET: this is the worldwide 
standard for the ﬁ elds in a clinical 
trials database, speciﬁ ed by the 
World Health Organization in 
November 2005
1. Unique trial number
2. Trial registration date
3. Secondary IDs
4. Funding sources
5. Primary sponsor
6. Secondary sponsors
7. Contact for public queries
8. Contact for scientiﬁ c 
queries
9. Public title of the study
10. Scientiﬁ c title of the study
11. Countries of recruitment
12. Health condition or 
problem studied
13. Interventions
14. Key inclusion and exclusion 
criteria
15. Study type
16. Date of ﬁ rst enrolment
17. Target sample size
18. Recruitment status
19. Primary outcome
20. Key secondary outcomes
The Australian Clinical Trials Registry has an 
advisory board with wide representation, including:
Australian chief medical oﬃ  cer Professor John Horvath
National manager of the 
Therapeutic Goods Administration Dr David Graham
Nominee of the Therapeutic Goods 
Administration Dr John Rankin
Chief executive oﬃ  cer of the NHMRC Mr William Lawrence
Nominee of the University of Sydney, 
independent of ACTR Professor Don Nutbeam
Chief investigator of the ACTR project 
(ex oﬃ  cio) Professor John Simes
Member or nominee of the NHMRC 
Research Committee Professor Terry Nolan
Member or nominee of Australian 
Health Ethics Committee Dr Garry Pearce
Industry representative Ms Deborah Monk
Representative of the clinical 
research community Professor Caroline Crowther
Editor of an ICMJE-aﬃ  liated medical journal Dr Martin Van Der Weyden
Health consumer advocate Dr John Stubbs
Chief Executive of the 
New Zealand Health Research Council  Dr Bruce Scoggins
Davina Ghersi
Director, systematic reviews and health care assessment
Lisa Askie 
ACTR manager
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Assessment of new technologies, 
diagnostic tests and procedures
The CTC has a contract with the Australian Government’s Medical Services Advisory 
Committee (MSAC) to review new and existing health technologies, diagnostic tests 
and procedures for which funding is sought under the Medicare Beneﬁ ts Schedule. 
Assessments for MSAC are based on a systematic review of the scientiﬁ c literature 
and other information sources, including clinical expertise. During 2004–2005, the 
CTC and clinical specialists completed several reviews of the evidence for funding new 
procedures.
Drug-eluting stents
Coronary artery stenosis is commonly treated by a stent, a small metal mesh expandable 
tube, which is inserted and expanded to scaﬀ old the vessel to improve blood ﬂ ow. A 
drug-eluting stent is coated with a drug that is gradually released to inhibit cell growth 
which may block the artery. A drug-eluting stent is much more costly than a bare-metal 
stent and has not been shown to reduce rates of death or myocardial infarction.
The review compared drug-eluting stents with bare-metal stents and found that on the 
strength of current evidence, drug-eluting stents reduced the rate of repeat procedures 
for up to one year and were as safe as bare-metal stents. There was insuﬃ  cient evidence 
to show a diﬀ erence in the rates of myocardial infarction, coronary artery bypass grafting 
or mortality. The technology is cost-eﬀ ective if a cost of $3700–$6200 is considered 
acceptable to avoid a target lesion revascularisation, but there is still uncertainty when 
the assumptions are varied to account for patients receiving more than one stent, the 
varied risks of the patients and the diﬀ erences between trial conditions and routine 
Australian clinical practice.
Positron emission tomography for lung cancer
Positron emission tomography (PET) uses short-lived radiopharmaceuticals to detect 
and assess perfusion and metabolic activity in various organ systems. 
The review team and the MSAC advisory panel developed two speciﬁ c questions in 
relation to non-small-cell lung cancer:
• What is the preoperative value of PET (using a radiolabelled analogue of glucose) 
plus usual staging in patients with potentially curable non-small-cell lung cancer?
• What is the additional value of PET in patients with a solitary pulmonary nodule 
where the results of conventional imaging or tests have been inconclusive or 
unavailable?
The review found that PET improved diagnostic accuracy when added to conventional 
staging of non-small-cell lung cancer. Also, for single nodules of more than 1 cm, PET 
is a potentially useful clinical aid when biopsy or conventional imaging are inadequate. 
Public funding for these indications was recommended.
Positron emission tomography (PET) for epilepsy
In about a quarter of epilepsy patients seizures cannot be adequately controlled by 
medical treatment, and some are considered for surgery. Positron emission tomography 
(PET) is sometimes used in addition to computed tomography (CT) and magnetic 
resonance imaging (MRI) to acquire information about the focus of the seizure before 
surgery.
Sally Lord 
Manager, health care assessment
»
New guidelines for 
assessing diagnostic 
tests
Assessments of diagnostic tests 
have been informed by a rapidly 
evolving body of research on 
the methods for conducting 
systematic reviews of diagnostic 
tests. 
In 2005 the CTC assisted MSAC 
in preparing a document, 
Guidelines for the assessment 
of diagnostic technologies, to 
guide review groups at the CTC 
and elsewhere. This document 
provides:
• guidelines: MSAC’s 
recommended methods for 
identifying, appraising and 
summarising evidence about 
the safety, eﬀ ectiveness 
and cost-eﬀ ectiveness of a 
diagnostic test
• assessment framework: 
MSAC’s approach for 
integrating and interpreting 
this evidence to draw 
conclusions about the net 
clinical beneﬁ t of the test.
A diagnostic test is deﬁ ned as 
any technology or procedure 
that is used to conﬁ rm, exclude 
or classify disease.
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This review of PET imaging found that the technology is safe; 
provides additional localising information in some patients, of 
whom a proportion will have good post-surgical outcomes as a 
consequence; and is likely to be cost-eﬀ ective in the long term.
SIR-Spheres for the treatment of nonresectable 
liver tumours
SIR-Spheres are yttrium-90 microspheres that are implanted 
into malignant liver tumours to deliver high doses of 
ionising radiation. They are used to treat liver metastases 
from colorectal cancer and hepatocellular carcinoma in 
combination with chemotherapy. The review compared the 
safety and eﬀ ectiveness of SIR-Spheres, alone or in addition to 
chemotherapy, with the alternative treatments.
Colorectal cancer is the most common cancer and the third 
most common cause of cancer death reported to Australian 
cancer registries, and hepatocellular carcinoma is the most 
common primary liver cancer. Optimising their treatments 
would have wide-ranging beneﬁ ts.
Although one trial reported improved survival with SIR-Spheres, 
further evidence is needed to determine the eﬀ ectiveness of SIR-
Spheres in combination with current systemic chemotherapy 
regimes.
Magnetic resonance cholangiopancreatography
Disorders of the pancreas and bile duct are typically manifested 
by pain or jaundice due to duct obstruction. Delayed treatment 
due to false-negative results and unnecessary procedures due 
to false-positive results are associated with serious risks to the 
patient. Common causes of obstruction include stones and 
stricture of the common bile duct. 
Magnetic resonance cholangiopancreatography (MRCP) is a 
specialised MRI technique that produces images of the bile 
ducts, pancreas and surrounding tissues. It was compared 
with computed tomography (CT) imaging and endoscopic 
retrograde cholangiopancreatography (ERCP, requiring patients 
to swallow an endoscope) in patients needing more than a 
conventional clinical assessment and ultrasound imaging.
The review found that MRCP was generally safer than ERCP 
and had better outcomes for some patients, depending on the 
surgical and other treatment they went on to have. It is likely to 
be as eﬀ ective as CT scanning for detecting bile duct stones. 
Brachytherapy to treat prostate cancer
Brachytherapy is the implantation of radioactive sources in or 
near tumours. For prostate cancer (the most common cancer in 
men), radioisotopes are inserted directly into the prostate gland. 
The radioactive sources destroy tumour cells of the prostate 
gland without signiﬁ cantly irradiating adjacent normal tissue.
Brachytherapy has been proposed as a more eﬃ  cient treatment 
(shorter treatment, time in hospital and recovery time) for 
localised prostate cancer, with the additional advantages of 
limiting the side-eﬀ ects to adjacent tissues that occur with 
conventional external-beam radiotherapy and the surgical risks 
associated with radical prostatectomy. However, the procedure 
may have short- and long-term complications.
The study compared iodine radioisotope brachytherapy and 
radical prostatectomy, external beam radiation therapy and 
active surveillance for treating early localised prostate cancer. 
The outcomes assessed included survival; tumour progression; 
urinary, rectal and sexual function; quality of life, and costs.
The evidence available did not show a diﬀ erence between the 
treatments in survival or disease progression; however the 
safety proﬁ les of the treatments were found to diﬀ er. There 
was not enough evidence to ascertain the cost-eﬀ ectiveness of 
strategies.
Current practices and future directions in 
the diagnosis, prevention and treatment of 
lymphoedema
Lymphoedema is the abnormal swelling of body tissues, most 
often in the limbs, caused by a failure of the lymphatic system, 
most often after cancer surgery. Aﬀ ected limbs become swollen 
and may be painful, normal function is compromised and 
recurrent infection can occur. 
There are currently no Australian standards for the treatment of 
lymphoedema. A review of lymphoedema in Australia showed a 
lack of high-quality evidence to support many of the treatments 
in use, professional education, training and resources.
Advances in treating cancer to reduce the risk of lymphoedema 
are being trialled in Australia and include the use of sentinel 
lymph node biopsy in the axillary staging of breast cancer (see 
page 20). 
Endometrial ablation techniques for chronic 
refractory menorrhagia
Endometrial ablation is a procedure that aims to destroy the 
endometrial lining of the uterus, causing a reduction in or 
elimination of menstrual bleeding. 
The review considered the safety, eﬀ ectiveness and cost-
eﬀ ectiveness of newer techniques of endometrial ablation 
available in Australia compared with earlier techniques in 
women with chronic refractory menorrhagia. The available 
evidence showed that second-generation endometrial ablation 
procedures appear to be at least as safe and as eﬀ ective as ﬁ rst-
generation endometrial ablation procedures.
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Urovysion assay for detecting recurrence of bladder cancer
Bladder cancer is common in Australia, particularly among men. The standard method 
for detecting recurrence of bladder cancer is cystoscopy, in which a ﬂ exible scope is 
inserted through the urethra of an anaesthetised patient. Urovysion ﬂ uorescence in situ 
hybridisation (FISH) assay is a new technique that detects chromosomal aberrations 
related to bladder cancer by treating and examining cells from a urine sample. The 
reviewers asked: what is the value of the Urovysion assay in conjunction with cystoscopy 
versus cystoscopy alone to diagnose recurrence of transitional cell carcinoma? The 
review showed that, for most patients,  the Urovysion test does not greatly increase 
the probability of detecting recurrence. For patients with a high risk of recurrence, the 
test may reduce the number of cystoscopies. A cost-eﬀ ectiveness model showed that 
including Urovysion in the clinical pathway increased the expected cost for patients, 
with no expected improvement in clinical outcomes.
Financial costs and quality of life are important to 
clinical decision making and health policy
How medical treatment aﬀ ects patient-oriented outcomes (such as survival, quality of 
life and preferences) and society-oriented outcomes (such as cost-eﬀ ectiveness and 
cost-utility) are critical for decision making in clinical practice and health policy. 
A focus of the CTC’s research program is continual improvement of the methods of 
assessing quality of life (see page 33) and calculating cost-eﬀ ectiveness and 
cost-utility. 
Better measurement of the costs and beneﬁ ts of hospital care
Measures of hospital eﬃ  ciency such as cost per case-mix-adjusted admission have 
been adopted for funding hospitals and for benchmarking and relative performance 
measurement. Current hospital funding mechanisms based on case-mix ignore 
diﬀ erences in quality or outcomes of care. Therefore, economic incentives are created to 
reduce quality to minimise the cost per admission. 
Such performance measures, which ignore the value of quality, encourage practices of 
quality-skimping, cost-shifting and ‘quicker, sicker’ care. Also, patients may need further 
care after they have been discharged from hospital. The costs of this care may not be 
counted in measures of hospital eﬃ  ciency. A better incentive is funding that depends on 
the quality of care, with an economic trade-oﬀ  between the cost and the value of care. 
A series of studies at the CTC has identiﬁ ed measures of eﬃ  ciency that include economic 
incentives for the quality of services in hospital and over time; that is, they measure 
relative provider performance consistent with an underlying objective of maximising net 
beneﬁ t. Included is a framework that includes data linkage and risk-factor adjustment to 
overcome incentives for cost-shifting and cream-skimming.
Simon Eckermann
Health economist
»
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HEALTH ECONOMICS 
VISITING FELLOW
Professor Andy Willan visited 
the CTC for four weeks in 
2005. Professor Willan is a 
biostatistician and clinical trial 
methodologist who is a senior 
scientist at the Hospital for 
Sick Children, professor in the 
department of Public Health 
Sciences at the University of 
Toronto and professor emeritus 
in the Department of Clinical 
Epidemiology and Biostatistics 
at McMaster University. 
He and Simon Eckermann 
presented a program of 
seminars demonstrating 
methods for net beneﬁ t analysis, 
expected value of information 
and optimal trial design.
Simon Eckermann and Alison Griﬃ  ths
Health economists
Cost-eﬀ ectiveness of 
pravastatin therapy 
in older people with 
coronary heart disease
The LIPID investigators recently 
carried out an economic analysis 
of the use of pravastatin in the 
younger compared with the 
older subgroup, to be published 
in 2006 (see page 31) .
HEALTH ECONOMICS
Uncertainty in cost-eﬀ ectiveness, predictive conditioning and 
extrapolation beyond the life of a trial
Decision making based on incremental cost-eﬀ ectiveness ratios has been aided by 
recent developments in estimating the range of the cost-eﬀ ectiveness ratio distribution 
from randomised trials using bootstrapping, a statistical method of repeated random 
sampling. However, the method can introduce structural uncertainty into estimation of 
precision. 
A methodological study at the CTC has identiﬁ ed a new way of increasing the precision 
of the incremental cost-eﬀ ectiveness ratio by combining within-trial and beyond-trial 
uncertainty. This informs decision makers of the relative uncertainties related to within-
study and beyond-study eﬀ ects.  
Systematic reviews of new technology: economic analyses
When systematic reviews of new technologies are undertaken for the Australian 
government (page 47), if the evidence shows that a technology, test or procedure has 
better health outcomes than current practice, a cost-eﬀ ectiveness analysis is also done. 
Such a comparison of the costs of the new and standard procedures is undertaken to 
assist decisions about the allocation of funding. Economic evaluations use a broad 
health-care-system perspective to identify which option might maximise the health 
beneﬁ ts or minimise the their cost. These studies include sensitivity analyses of 
incremental eﬀ ects, costs and cost-eﬀ ectiveness.
The CTC’s health economists work alongside the CTC’s systematic reviews team on 
the health economic component of MSAC reviews. In 2005 these and similar reviews 
included brachytherapy for prostate cancer and Urovysion, an assay for detecting 
recurrence of transitional cell carcinoma of the bladder.
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Models to predict risk for individual patients
The results of a clinical trial may show that treatment reduces the risk of an event across 
a broad range of patients. However, patients are diﬀ erent in many ways, including their 
initial risk. For example, a treatment may beneﬁ t older patients more because their risk 
is intrinsically higher.
Large multicentre trials can amass data from thousands of patients over many years. 
Analysis of the clinical course of these patients allows us to accurately estimate risks in 
groups of patients with various common characteristics and then to determine how 
diﬀ erent factors predict risk. Thus, pragmatic risk factor tools can be created to assess 
risk and guide decisions about treatment for individual patients.
A model of long-term cardiovascular risk from the LIPID trial
LIPID was the CTC’s ﬁ rst large cardiovascular prevention trial. The LIPID cohort, now 
followed up for over 11 years, has been used to develop a prognostic model for coronary 
mortality among patients who have been admitted to hospital for a coronary heart 
disease event (see page 31). 
Important independent risk factors for CHD death, in a Cox regression analysis, were 
older age, prior myocardial infarction, cardiac symptoms of angina or dyspnoea, 
male sex, diabetes mellitus, smoking, high white cell count, low HDL cholesterol, 
hypertension, prior stroke and atrial ﬁ brillation. Coronary revascularisation after (but 
not before) an acute CHD event and pravastatin treatment both reduced the risk of CHD 
death. 
A risk score based on these factors enabled patients to be classiﬁ ed into three risk 
categories, with 4.7%, 11.5% and 32.8% 
risk of death from coronary heart disease 
over ten years. Those in the higher-risk 
group could expect more beneﬁ t from 
pravastatin treatment.
The LIPID risk model for CHD death 
provides a simple but eﬀ ective means of 
identifying patients at very high or low 
risk of CHD death, which should be a 
practical guide for stratifying patients for 
more conservative or intensive treatment 
strategies and for choosing patients for 
participation in future clinical trials.
These results were presented at the 
annual scientiﬁ c meeting of the American 
Heart Association in Dallas in November 
2005.
RISK MODELS
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Using international data for a model of risk after acute 
myocardial infarction
The HERO-2 trial (Hirulog early reperfusion occlusion) was a large international trial in 
47 countries of two antithrombosis treatments for acute myocardial infarction. HERO-2 
recruited 17 073 patients, who received bivalirudin or unfractionated heparin by random 
allocation.
Baseline patient data from this trial were used to develop a prognostic index (HERO-2 
prognostic index, HPI) of the risk of death within 30 days after myocardial infarction. 
Factors contributing to risk included age, blood pressure, heart rate and the location 
of the myocardial infarction. Because of the global distribution of patients, this study 
provided a rare opportunity for comparing the new prognostic index with earlier indices 
developed in Western populations by allowing internal calibration to populations from 
other regions.
The prognostic index performed well in internal validation and predicted risk in an 
external data set of Western patients, but is still to be tested in non-Western data sets. 
HERO-2 has also been an opportunity to explore and validate the statistical methods 
for building a prognostic model. The ﬁ rst of these statistical studies will be ready for 
publication in 2006.
HERO-2 
PROGNOSTIC INDEX
Rachel O’Connell, a CTC 
statistician, has been using the 
data set from the HERO-2 trial 
for research on risk models in 
her PhD project. 
She has been developing the 
HERO-2 prognostic index 
(HPI). The HPI applies well 
internationally and is likely to be 
useful in many clinical settings.
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APPLYING TRIAL RESEARCH TO INDIVIDUAL PATIENTS: RISK MODELS AND PREFERENCES
Eliciting preferences from cancer patients
to improve decision making
Anticancer treatments improve survival rates, delay progression of the disease and 
improve cancer-related symptoms, but they also have side-eﬀ ects and are inconvenient. 
The average beneﬁ ts conferred by adjuvant chemotherapy for groups of women with 
early breast cancer are well-established and beyond reasonable doubt, but the actual 
beneﬁ t for any particular woman cannot be known. Many women judge small beneﬁ ts 
suﬃ  cient to make the side-eﬀ ects and inconvenience worthwhile.
The important question for patients and clinicians is: for individual patients, how much 
beneﬁ t is needed to make the additional side-eﬀ ects and inconvenience worthwhile?
Vlatka Duric and Martin Stockler of the CTC and their colleagues are examining this 
question in a series of studies in which people who have experienced the treatment 
are asked to weigh the beneﬁ ts and harms of anticancer treatments, particularly 
chemotherapy. Participants identify the smallest improvement in survival time or 
survival rate they judge necessary to make that therapy worthwhile.
Comparing patients’ and their partners’ preferences for adjuvant 
chemotherapy in early breast cancer
Clinicians often include the life partners of patients with breast cancer in making 
decisions about treatments. In this study, both patients and their partners were 
interviewed. Cancer patients’ and partners’ judgments of the value of adjuvant 
chemotherapy diﬀ ered considerably and included considerations other than length and 
quality of life.
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Vlatka Duric and Martin Stockler
PATIENT PREFERENCES STUDIES
Vlatka Duric completed a PhD in psychological medicine from the University of Sydney at the CTC.
Her subject was patient preferences—to determine how individuals trade oﬀ  the beneﬁ ts, harms and uncertainties of 
chemotherapy treatment adjuvant to surgery for early breast cancer.
Preferences were highly variable, but many judged marginal beneﬁ ts suﬃ  cient to make chemotherapy worthwhile. Patients 
and their life partners had diﬀ erent preferences, but not systematic diﬀ erences in their preferences. Psychosocial factors 
explained only some of the variation.
Patients’ preferences, quality of life and adjuvant radiation 
therapy for women with early breast cancer
Radiation therapy reduces the risk of local recurrence but has little eﬀ ect on survival in 
women with small breast cancers. Preferences for adjuvant radiation were elicited from 
95 women who had had it after surgery. Most women judged small beneﬁ ts suﬃ  cient 
to make the radiation therapy worthwhile.
Results were presented at the annual scientiﬁ c meetings of the Clinical Oncological 
Society of Australia and the Royal Australian and New Zealand College of Radiologists 
in 2005.
Adjuvant endocrine therapy in early breast cancer: what makes it 
worthwhile?
Endocrine (hormone) therapy for breast cancer may cause menopausal symptoms, 
infertility and osteoporosis. The side-eﬀ ects of endocrine therapy may be less intense 
than those of chemotherapy, but they could be more important than clinicians realise. 
In a collaboration with UK researchers, a sample of women with early breast cancer 
taking part in a trial of endocrine therapy were interviewed. The results of this study 
were published recently in the British Journal of Cancer. The ﬁ ndings were unexpected: 
women having endocrine therapy needed bigger beneﬁ ts to make treatment 
worthwhile than women having chemotherapy.  This suggests that shorter treatments, 
such as chemotherapy, may be easier to cope with, even if the side-eﬀ ects are more 
severe.
Patients’ preferences for adjuvant 
chemotherapy in early colon cancer: what 
makes it worthwhile?
This project will determine the preferences of patients 
who have had adjuvant chemotherapy for early colon 
cancer. Preferences are elicited by a questionnaire and 
a face-to-face interview. In a related study, clinical 
researchers and medical oncologists were surveyed by 
questionnaire on the same topic. 
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budget advisory committee and faculty awards 
committee
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Breast Cancer Group, Central Register of 
Controlled Trials advisory group 
International Clinical Trials Registry Platform, 
World Health Organization, scientiﬁ c advisory 
group, and chair, WHO Registers Working 
Group
NSW Cancer Council Cancer Trials NSW trial 
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NSW Health Pilot Shared Scientiﬁ c Assessment 
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Prospective meta-analysis of weight 
management in childhood and adolescent 
obesity management committee
University of Sydney course advisory 
committee, MHlthSc and Graduate Certiﬁ cate 
in Health Science (Clinical Data Management)
Wendy Hague
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Thromboembolism (ASPIRE) trial management 
committee
Beneﬁ ts of Oxygen Saturation Targeting 
(BOOST II) management committee
International Neonatal Immunotherapy 
Study (INIS) Australian and New Zealand 
management committee
Long-Term Intervention with Pravastatin 
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Sally Lord
HTAi 2006 (3rd Annual Meeting of Health 
Technology Assessment International) scientiﬁ c 
committee 
Anna Nowak
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Sharon Parker
Cochrane Collaboration colloquium policy 
advisory group
Clinical practice guidelines for communicating 
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(TROG) and the Australasian Gastro-Intestinal 
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resource group
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